

UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE
Curriculum Vitae

Date: 07/07/2022

Joel M. Gelfand, MD MSCE

Address: Perelman Center for Advanced Medicine
7th Floor, South Tower
Suite 730
Philadelphia, PA 19104 USA

If you are not a U.S. citizen or holder of a permanent visa, please indicate the type of visa you have:
none (U.S. citizen)

Education:

1993	B.S.	Tufts University (Biology, Community Health)
1998	M.D.	Harvard Medical School
2003	M.S.C.E.	University of Pennsylvania (Epidemiology)

Postgraduate Training and Fellowship Appointments:

1998-1999	Intern in Medicine, Mount Sinai Hospital, New York, NY
1999-2002	Resident in Dermatology, Hospital of the University of Pennsylvania
2002-2003	Epidemiology Research Fellow, Hospital of the University of Pennsylvania

Military Service:

[none]

Faculty Appointments:

2002-2003	Instructor, Department of Dermatology, University of Pennsylvania
2003-2012	Assistant Professor of Dermatology, University of Pennsylvania School of Medicine
2010-2012	Assistant Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary)
2012-2016	Associate Professor of Dermatology, University of Pennsylvania School of Medicine
2012-2016	Associate Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary)
2016-2021	Professor of Dermatology, University of Pennsylvania School of Medicine
2016-present	Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary)
2021-present	James J. Leyden, M.D. Endowed Professor in Clinical

Investigation, University of Pennsylvania School of Medicine

Hospital and/or Administrative Appointments:

2002-2006	Director Consultative Dermatology, Presbyterian Medical Center
2003-present	Medical Director, Clinical Studies Unit, Department of Dermatology, Hospital of the University of Pennsylvania
2003-2004	Director Consultative Dermatology, Pennsylvania Hospital
2016-present	Vice Chair of Clinical Research, Department of Dermatology, University of Pennsylvania
2021-present	Endowed Professorship, James J. Leyden, M.D. Endowed Professorship in Clinical Investigation

Other Appointments:

2002-2003	Faculty Fellow, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
2004-2010	Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
2008-present	Associate Fellow, Center for Public Health Initiatives, University of Pennsylvania
2010-present	Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
2013-present	Director, Patient Centered Outcomes Research Track, Master of Science in Clinical Epidemiology Degree Program
2015-present	Medical Director, Psoriasis and Phototherapy Treatment Center, Department of Dermatology, University of Pennsylvania

Specialty Certification:

2002	Diplomat, American Board of Dermatology. Re-certified: 2011
------	---

Licensure:

2001	Pennsylvania
------	--------------

Awards, Honors and Membership in Honorary Societies:

1991	Hughes Foundation Undergraduate Research Fellow
1993	Summa Cum Laude, Tufts University
1993	Phi Beta Kappa
1993	Class of 1947 Victor Prather Prize Scholarship
1993	Thomas and Emily Carmichael Prize Scholarship
1996	Carl W. Walter Research Fellowship, Harvard Medical School
1997	Mount Sinai Department of Dermatology Research Award
1998	Magna Cum Laude, Harvard Medical School
2001-2003	National Institutes of Health National Research Service Award for Individual Postdoctoral Fellows (F32)

2001	The College of Physicians of Philadelphia Johnson Beerman Award
2002-2006	NIH Clinical Research Medical School Loan Repayment Award
2003	American Skin Association Outcomes Research Award
2003	Dermatology Foundation Career Development Award
2007-2016	Best Doctors in America
2008	Visiting Professor, University of Kentucky, Louisville, KY
2009	Keynote Lecturer: Dermatology Foundation Clinical Symposia
2010	13th Annual Visiting Professor. Saint Louis University Department of Dermatology
2011	The Samuel L. Moschella Lecturer, Lahey Clinic, Burlington MA
2011	Marjorie A. Bowman New Investigator Research Award, University of Pennsylvania Perelman School of Medicine
2011	Keynote Speaker, Murdough Family Center for Psoriasis Research Symposium at Case Western Reserve School of Medicine, Cleveland, OH
2011	American Skin Association Achievement Award for Psoriasis
2012	Chicago Dermatological Society David Fretzin Lecture
2012	The Henry Lewis Lecturer, University of Colorado
2013	Elected Member, American Dermatological Association
2013	The Odland Lecture, University of Washington, Division of Dermatology, Seattle, Washington
2013	Elected Member, American Society for Clinical Investigation
2014	Keynote Lecturer: Dermatology Foundation Clinical Symposia
2014	Lamar Osment Lectureship, University of Alabama at Birmingham
2014	Society for Investigative Dermatology: Eugene M. Farber Lecture
2015	Keynote lecturer, University of Pennsylvania Society for Clinical Research Coordination and Management annual meeting
2015	Keynote lecture, Interdisciplinary Autoimmune Summit Annual meeting, New York, NY
2015	Excellence in Teaching Epidemiology Award, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine
2016	Presidential Citation, American Academy of Dermatology
2017	Outstanding scientific achievement, National Psoriasis Foundation (Inaugural award winner)
2017	Marion B Sulzberger MD Memorial Award and Lectureship, American Academy of Dermatology
2017	Top 5 Psoriasis Paper International Psoriasis Council Outstanding Educator in Psoriatic Disease Award, National Psoriasis Foundation

2018	Honorary Member, Iranian American Dermatology Association
2019	Article selected as "Game changer" by the Journal of the American Academy of Dermatology (Psoriasis and the risk of diabetes: A prospective population-based cohort study)
2019	Article selected as "Best of the best in psoriasis" by JAAD (Prevalence of clinically significant incidental findings by whole-body 18 FDG-PET/CT scanning in moderate-to-severe psoriasis patients participating in clinical trials)
2019	Lady Barbara Colyton Prize for autoimmune research, University of Pennsylvania
2020	Top Doctor in Philadelphia Magazine
2021	The John Person Lecturer, University of Massachusetts
2021	Article selected as "Best of the best in psoriasis" by JAAD (The risk of RTI psoriasis patients treated with IL 17 biologics: A meta-estimate relevant to decision making during the COVID-19 pandemic)
2021	Best of the Best, "National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1"
2022	Founders Award, American Dermatoepidemiology Network
2022	Top Doctor, Castle Connolly

Memberships in Professional and Scientific Societies and Other Professional Activities:

International:

2006-Present	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
2006-Present	International Society for Pharmacoepidemiology
2007	Health Research Board, Ireland (Selected Grant Referee)
2007	National Institute for Health Research, United Kingdom (Selected Grant Referee)
2008	National Institute for Health Research, United Kingdom (Selected Grant Referee)
2009-Present	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (Steering Committee Member (Elected 2010-2016))
2010	PhD Committee for M. Wakkee (candidate), Erasmus University, Rotterdam, Netherlands (Selected Member. April 2010)
2010	The Physicians' Services Incorporated Foundation, Toronto, Canada (Selected Grant Referee)
2011-Present	International Psoriasis Council (Councilor)

2012	United States-Israel Binational Science Foundation (Grant Review Panel Member)
2013-2017	Data Safety Monitoring Board, Merck, Phase III Psoriasis Program (Chair 2013-2017)
2014-2021	Scientific Advisory Committee (Elected) Psolar registry (sponsor Jansen Biotech) (Elected Chair 2014)
2018-Present	Data Safety Monitoring Board, UCB, Phase III Bimekizumab Program (Chair)
2020-2022	Data Review Committee Lebrikizumab program Dermira/Lilly
2020-Present	Data Review Committee ORAL DIFELIKEFALIN program Cara
2020-Present	Data review committee NeuroDerm
2020-Present	Psoriasis Council Board of Directors (Member)
2021-Present	Data Review Committee (DRC) CellDex (prurigo nodularis program)
2021-Present	Global Steering Committee, Psolar registry (Jansen) (Elected chair)
<u>National:</u>	
1996-Present	Massachusetts Medical Society (Member)
1999-Present	Society for Investigative Dermatology (Member 1999; Member, Strategic Planning Committee 2002; Elected Member, Board of Directors 2002-2003; Member, Committee of Resident/Fellows Programs 2002-2003; Member, Committee on Albert M. Kligman Fellowship 2004; Member, Resident Retreat Organizing Committee 2012-14; Chair of the 2014/15 Resident Retreat Task Group)
2001-Present	American Academy of Dermatology (Selected Member, Resident Fellow Committee 2001-2002; Chair, Resident Fellow Committee 2002; Elected Member, Board of Directors (Resident Observer) 2002; Selected Member, Guidelines/Outcome Task Force 2004-2009; Selected Member, Young Physicians Committee 2004-2008; Selected Member, Workgroup on Pay for Performance Evidence Based Purchasing 2006-2007; Diplomat 2002; Selected Member, Environment and Drugs Committee 2009-2011; Selected Member, Adverse Event and Medical Errors Reporting Workgroup 2009;

Selected Member, FDA Liason Task Force 2009-2011;
 Selection Committee, Young Investigators in Dermatology Award 2011-2012,
 Outcomes Work Group Member 2013, Data Collection Work Group Member 2013,
 Research Committee Member 2014, Selected Member, Psoriasis Guidelines
 Committee 2018)

- 2002-Present American Board of Dermatology (Diplomat 2002-current; Member, Basic Science Curriculum Committee 2010-2011)
- 2002-Present Dermatology Foundation (Post Resident Member 2002; Member, Medical and Scientific Committee 2011-2014)
- 2005-Present National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) (Selected Member, NIH/NIAMS Study Section, Contract on Innovative Therapies for Rheumatic and Skin Diseases 2005; Selected Member, Challenge Grant Peer Reviewer July 2009; Selected Member, NIAMS ACTS Study Section on Small Business Applications, October 2009; Selected Member, NIAMS Roundtable on Clinical Trials in Skin Diseases, December 11, 2009; Special Emphasis Panel/ Scientific Review Group- Clinical Trials Planning, Pilot and Research Grants 2011)
- 2005-Present National Psoriasis Foundation (Selected Member, Medical Board 2005-2010; Selected Member, Grants Review Committee 2007,2014, Selected Member Scientific Committee 2009-current)
- 2006-2011 Veterans Affairs, Washington, D.C. (Selected Member, Scientific Review Panel October 17, 2006; Selected Member, Scientific Review Panel June 13, 2007; Selected Member, Scientific Review Panel December 20, 2011)
- 2008-2013 The FDA/CDER Office of Surveillance and Epidemiology (Appointed member, Special Government Employee to the Drug Safety and Risk Management Advisory Committee)
- 2009-2011 American Dermatoepidemiology Network (Secretary Treasurer)
- 2010-Present Medical Dermatology Society (Member)
- 2010-Present The Agency for Healthcare Research and Quality (Key Informant, Federal Advisory Panel- Psoriasis Technical Brief)
- 2013-Present American Dermatological Association (Elected Member)
- 2013-Present American Society for Clinical Investigation (Elected Member)
- 2013-Present Penn Center for Orphan Disease Research and Therapy

- 2014-Present Advisory Committee Boston University's NIAMS Multidisciplinary Clinical Research Center (P60)
- 2014-2015 American Society for Dermatoepidemiology (Elected Vice President 2014-2015)
- 2014-2016 Data Safety monitoring board Coherus Biosciences
- 2014-Present National Multiple Sclerosis Society Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) (Review Committee Member 2014-Present)
- 2015-2016 American Society for Dermatoepidemiology ((Elected President))
- 2017-Present NIAMS Ad hoc AMSC study section member
- 2017-Present NIH/NIAMS Selected Member Roundtable about Psoriatic Arthritis
- 2020-Present NIH/NIAMS invited member Clinical Studies Roundtable, Bethesda MD ()
- 2022-Present Scientific Director FORWARD psoriasis registry

Local:

- 2003-Present Cancer Center, University of Pennsylvania (Selected Member)
- 2008-Present Institute for Translational Medicine and Therapeutics, University of Pennsylvania (Selected Member)
- 2010-Present PENN Institute for Immunology
- 2010-Present Pennsylvania Academy of Dermatology and Dermatologic Surgery (Member)

Editorial Positions:

- 2001-2010 Continuing Medical Education Editor, Dermatology section/Emedicine
- 2002-Present Ad hoc Reviewer: Journal of Investigative Dermatology, Journal of the American Academy of Dermatology, Journal of Dermatological Treatment, Journal of Rheumatology, Journal of the National Cancer Institute, The Lancet, Medscape General Medicine, Pharmacogenomics, PLoS One, Therapeutics and Clinical Risk Management, Arthritis & Rheumatism, Journal of Clinical Rheumatology, Clinical Cancer Research, Pharmacogenomics
- 2002-Present Ad hoc Reviewer: Archives of Dermatology, Archives of Internal Medicine, Atherosclerosis, Canadian Medical Association Journal, Circulation, Consultant, Drugs and Aging, Drug Benefit Trends, Expert Review of Clinical Immunology, Journal of the American Medical Association, Journal of Clinical Investigation, Journal of

	Clinical Epidemiology, Journal of the European Academy of Dermatology and Venereology, Journal of Medicinal Chemistry, European Journal of Dermatology
2006-2017	Associate Editor/ Pharmacoepidemiology and Drug Safety
2010-Present	Editorial Board Member, Latin American Journal of Psoriasis and Psoriatic Arthritis
2011-2016	Associate Editor, Journal Watch, Special Section - Behind the numbers
2011-2013	Section Editor, Current Dermatology Reports
2011-2018	Editorial Board Member, Journal of the American Academy of Dermatology
2015-Present	Editorial Board Member, The Journal of Psoriasis and Psoriatic Arthritis
2017-2022	Deputy Editor, Journal of Investigative Dermatology
2022-Present	Deputy Editor, Clinical research and epidemiology, Journal of Investigative Dermatology

Academic and Institutional Committees:

2002-2003	Clinical Effectiveness and Quality Improvement Committee
2006-Present	Selected Member, UPENN Clinical Trials Advisory Committee
2008	Clinical Trials Advisory Committee Subcommittee on Contracts
2008-2010	Office of Research Services Advisory Committee
2011	Selection Committee, UPENN School of Medicine's Clinical Research Coordination Award for Research Excellence (C.A.R.E)
2011	Dean's Preliminary Inquiry Committee for Allegations of Scientific Misconduct
2012	Selection Committee, Marjorie A. Bowman New Investigator Research Award
2012	CCEB Service Center Committee
2012	Peer Reviewer for UPHS/CHOP/ITMAT Comparative Effectiveness Research Pilot Study Program
2012-2015	Office of Human Research Faculty Advisory Committee
2012-2017	Clinical Research Executive Committee, Department of Dermatology
2013-2015	Investigational Drug Services Faculty Advisory Committee
2013-Present	Department of Dermatology Committee on Appointments and Promotions (COAP)
2013-Present	University of Pennsylvania Disciplinary Panel Member
2013-Present	Member, Department of Dermatology Search Committee for Tenure Faculty
2014-2017	Elected Member, Medial Senate Steering Committee, Perelman School of Medicine, University of Pennsylvania
2014-Present	Chair, Department of Dermatology Search Committee for Clinician Educators
2014-Present	Selected member, Human Research Advisory Committee, University of Pennsylvania (reporting to the Vice Provost for Research)

2015-Present	Chair, Department of Dermatology Search Committee for Instructor A
2015-Present	Member, Search Committee CCEB CE and Tenure Track position in patient centered outcomes research
2015-2016	Member, Dean's Review Committee for the Department of Ophthalmology
2017-Present	Chair, Department of Dermatology Committee on Appointments and Promotions
2018	Ad hoc member, Department of Emergency Medicine, Committee on Appointments and Promotions, University of Pennsylvania Perelman School of Medicine
2019-2021	Member, Research Subcommittee of the UPHS Pharmacy and Therapeutics Committee
2019	Member, Professional Development Teaching Committee: Sub-Group Lecturing
2019	Ad hoc Advisor for Faculty Promotion, Yale University School of Medicine
2020-2022	Member, IPC Board of Directors
2020	Ad hoc voting member Perelman School of Medicine Committee on Appointments and Promotions
2020-2021	Member, selection committee for The Lady Barbara Colyton Prize for Autoimmune Research
2020-Present	Co-Chair, National Psoriasis Foundation COVID-19 Task Force
2021	Member, University of Pennsylvania University Research Foundation Biomedical Review Panel
2022	Member, Department of Surgery Review Committee

Major Academic and Clinical Teaching Responsibilities:

2002-Present	Lectures to internal medicine and dermatology house staff (approximately 3-4 lectures per year)
2002-Present	Supervise resident outpatient clinic (one half day per month)
2002-2004	Supervise resident consults on inpatients at Presbyterian Medical Center(3 days/week)
2002-Present	Supervise resident consults on inpatients at the Hospital of the University of Pennsylvania (one month per year)
2003-Present	Mentor for MSCE students (approximately 1-3 hours per week)
2003-Present	CME lecturer at American Academy of Dermatology and US Dermatology Departments (approximately 12 lectures per year)
2015-Present	Course Director, EPID624: Methods in Patient Centered Outcomes Research
2015-Present	Psoriasis curriculum development and lectures for medical students (Derm 200) and dermatology residents (GME)
2016	"Psoriasis: Epidemiology, Pathophysiology, and Treatment," Allergy Grand Rounds, University of Pennsylvania, Philadelphia, PA

Lectures by Invitation (Last 5 years):

- Mar, 2017 "Comorbidity in Psoriasis" IPC IEC Symposium, Orlando, FL
- Mar, 2017 "Impact of psoriasis biologics on cardiovascular risk: relevance for clinical practice," American Academy of Dermatology Annual Meeting, Orlando, FL
- Mar, 2017 "Getting to the heart (and other comorbidities) in psoriasis" American Academy of Dermatology Sulzberger Lecture, Orlando, FL
- Apr, 2017 "Registries: Lessons from pharmacoepidemiology and psoriasis" Regeneron. Tarrytown NY
- Jun, 2017 "Registries: Methods and Musing" Psolar meeting, Philadelphia PA (international meeting)
- Oct, 2017 "Psoriasis update". GSK, Collegeville PA
- Nov, 2017 "The THRIVE Initiative: New Biologics for Patients with Psoriasis: An Oculus Virtual Reality View" CME Program Las Vegas, NV
- Dec, 2017 "Impact of Psoriasis on HrQOL and Comorbidity. Academy of Managed Care Pharmacy". Arlington VA
- Jan, 2018 "Update on Psoriasis Comorbidity" Maui Derm. Wailea, HI. Psoriasis Update: CME Outfitters (Online web program)
- Jan, 2018 "An Oculus Virtual Reality View of New Biologics to Improve Outcomes and Quality of Life for Patients with Psoriasis" CME Program Aruba
- Jan, 2018 "Psoriatic disease update" Pfizer, Collegeville, PA
- Feb, 2018 "A Phase IV, Randomized, Double-Blind, Placebo-controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U trial)," American Academy of Dermatology Annual Meeting, San Diego, CA
- Feb, 2018 "A Phase IV, Randomized, Double-Blind, Placebo-controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U trial)," Skin Disease Education Foundation's 42nd Annual Hawaii Dermatology Seminar, Kauai, HI
- Feb, 2018 "Cardiovascular risk in psoriasis: Implications for your clinical practice" Psoriasis Symposium American Academy of Dermatology, San Diego, CA
- Feb, 2018 "Cardiovascular risk in psoriasis: Implications for your clinical practice," American Academy of Dermatology Annual Meeting, San Diego, CA
- Apr, 2018 "Cardiovascular comorbidity in psoriasis" and "Treat to target: an old paradigm new to psoriasis" DermAcademy, Colonia Uruguay
- Apr, 2018 "Treat-to-target: An old paradigm new for psoriasis?" Novartis Argentina for Cosentyx psoriasis, Uruguay
- Apr, 2018 "New Biologics for Improved Skin Clearance in Psoriasis," Interdisciplinary Autoimmune Summit, Boston, MA
- Apr, 2018 "New Advances in the Treatment of Moderate-to-Severe Psoriasis: A Focus on IL-23-Targeted Agents," Interdisciplinary Autoimmune Summit, Boston, MA
- Apr, 2018 "New Advances in the Impact of Anti-Inflammatory Treatment on

- Cardiovascular Risk, Interdisciplinary Autoimmune Summit, Boston, MA
- May, 2018 "A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial" Oral Presentation, International Investigative Dermatology Meeting Orlando, FL
- May, 2018 A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial, International Investigative Dermatology Meeting, Orlando, FL
- Jun, 2018 "Comparative Effectiveness Studies," FDA course, Silver Spring, MD
- Oct, 2018 "Let's be real (world): Getting pragmatic about clinical trials, Yale University, New Haven, CT
- Oct, 2018 "Psoriasis and CV Risk: Causes and Consequences," Janssen AD Board, Jersey City, NJ
- Oct, 2018 "Clinical Practice Implications of Psoriasis Comorbidity Research," Yale University, New Haven, CT
- Nov, 2018 "Skin Clearance, Quality of Life and Other Patient-Centered Psoriasis Goals: Implications of Biologic Treatment," Society of Dermatology Physician Assistants Annual Meeting, Orlando, FL
- Nov, 2018 "Let's be real (world): Getting pragmatic about clinical trials," International Psoriasis Council Think Tank, Miami Beach, FL
- Dec, 2018 "Psoriasis and Cardiovascular Disease Update: Hot Off the Presses," NYU Advanced Seminar in Psoriasis and Psoriatic Arthritis, New York, NY
- Dec, 2018 "Impact of immune targeted therapy on cardiovascular risk: The psoriasis model," Inflammatory Skin Disease Summit, Vienna, Austria
- Dec, 2018 "Does Psoriasis Treatment Affect Cardiovascular Disease?," Inflammatory Skin Disease Summit, Vienna, Austria
- Jan, 2019 "Update on psoriasis comorbidities," Maui Derm, Wailea, HI
- Feb, 2019 "Biologic Agents for a Personalized Approach to Psoriasis," Skin Disease Education Foundation (SDEF) Annual Meeting, Kona, HI
- Feb, 2019 "Psoriasis and Comorbidity: A primer for clinicians," UC Irvine Grand Rounds, Irvine, CA
- Mar, 2019 "The VIP-S Trial: Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects with Moderate to Severe Plaque Psoriasis (NCT02690701)," American Academy of Dermatology Annual Meeting, Washington, DC
- Apr, 2019 "Optimizing Therapeutic Selection for Common Comorbidities and Special Patient Populations with Psoriasis: A Case-Based Approach," Interdisciplinary Autoimmune Summit, Chicago, IL
- Apr, 2019 "Psoriasis and cardiovascular disease: epidemiological and

- interventional clinical trials research," China Dermatologist Association, Beijing, China
- Apr, 2019 "Pragmatic trials: Research that reflects real world clinical practice," China Dermatologist Association, Beijing, China
- Apr, 2019 "Update on Cardiovascular Risk in Immune-Mediated Inflammatory Diseases," Interdisciplinary Autoimmune Summit, Chicago, IL
- Apr, 2019 "Translating Current and Emerging Therapies into Enhanced Management Strategies for Psoriasis: A Focus on the IL-17 and IL-23 Pathways," Interdisciplinary Autoimmune Summit, Chicago, IL
- Apr, 2019 "Update on Cardiovascular Risk in Immune-Mediated Inflammatory Diseases, Interdisciplinary Autoimmune Summit, Chicago, IL
- Apr, 2019 "Optimizing Therapeutic Selection for Common Comorbidities and Special Patient Populations with Psoriasis: A Case-Based Approach," Interdisciplinary Autoimmune Summit, Chicago, IL
- Apr, 2019 "Translating Current and Emerging Therapies into Enhanced Management Strategies for Psoriasis: A Focus on the IL-17 and IL-23 Pathways," Interdisciplinary Autoimmune Summit, Chicago, IL
- May, 2019 "Effect of psoriasis treatment on cardiovascular risk: Reconciling clinical trials and observational studies," Society for Investigative Dermatology
- Oct, 2019 "Psoriasis Comorbidity Part 1," National Psoriasis Foundation Annual Residents Meeting, Philadelphia, PA
- Oct, 2019 "Phototherapy, Other Light Sources and the LITE Study," National Psoriasis Foundation Annual Residents Meeting, Philadelphia, PA
- Oct, 2019 "The Patient Journey: Unmet Need in the Treatment Landscape and Associated Comorbidities," European Academy of Dermatology and Venereology Annual Meeting, Madrid, Spain
- Jan, 2020 Comparative Effectiveness Research in Action: The LITE Study
- Mar, 2020 Cochrane International meeting on Comparative Effectiveness Research, Denver, CO.
- May, 2020 "Effect of psoriasis treatment on cardiovascular risk: Reconciling clinical trials and observational studies," AAD Virtual Annual Meeting
- May, 2020 "Coping with COVID - Psoriasis," HCPLive® Psoriasis Webinar
- Jun, 2020 "Cardiovascular Disease in Psoriasis: A Western Perspective on Scientific Progress and Clinical Implications," The 119th Annual meeting of the Japanese Dermatological Association Tokyo Japan
- Jul, 2020 "COVID19 IAS Roundtable," Interdisciplinary Autoimmune Summit
- Jul, 2020 "IAS - Session: Effect of biologic and small molecule treatment on cardiovascular risk: Reconciling clinical trials and observational studies," Interdisciplinary Autoimmune Summit
- Jul, 2020 "The Current State of Psoriasis Treatment with Targeted Therapy," Interdisciplinary Autoimmune Summit

Sep, 2020	"System Challenges to Inclusion of Vulnerable Populations in Pragmatic Trials: The LITE Study Experience," PCORI Annual Meeting, Washington DC
Sep, 2020	"Psoriasis Management in the Time of COVID-19," Maui Derm Connect
Sep, 2020	"COVID-19 Update," National Psoriasis Foundation Psoundbytes Webinar
Oct, 2020	"Psoriasis Case Study," Keystone Dermatology Meeting, Philadelphia PA
Oct, 2020	"Dermatologist and Rheumatologists Co-Managing Psoriatic Arthritis," American College of Rheumatology Annual National Meeting (virtual)
Oct, 2020	"Managing Biologics & Comorbidities in Psoriasis," Keystone Dermatology Meeting, Philadelphia PA
Oct, 2020	"Phototherapy, Other Light Sources and the LITE Study," National Psoriasis Foundation Annual Resident Education Meeting
Oct, 2020	"Psoriasis and COVID19 update," National Psoriasis Foundation Annual Resident Education Meeting
Dec, 2020	"COVID risk of biologics from published literature: 2020 IPC Think Tank," International Psoriasis Council Annual Meeting
Jan, 2021	"Review of Real-World COVID-19 Outcomes Data: Patients With Immune-Mediated Inflammatory Diseases-Part 2," Winter Clinical Dermatology Meeting (Hawaii -virtual)
Jan, 2021	"Implications of the COVID19 pandemic on management of psoriasis, Maui Derm 2021 (Maui Hawaii virtual)
Feb, 2021	"Social Media in Dermatology: An N of 1 observational study," Pediatric Dermatology Research Alliance
Mar, 2021	"Hot Topics in Biologics for Psoriasis: Impact on Cardiovascular Disease and COVID-19," Medscape CME program
Mar, 2021	"COVID-19 and the Impact on Patients With Psoriatic Disease," Medscape CME program
Mar, 2021	"Psoriasis and Cardiovascular Disease," Bristol Myers Squibb Expert Lecture Series
Apr, 2021	"Testing a new strategy to improve prevention of cardiovascular disease in patients with psoriasis: The coordinated care model," NHLBI Prevention of Cardiovascular Disease in Patients with Psoriasis and Psoriatic Arthritis: Bridging the Evidence to Practice Gap for Statins Virtual Meeting
Apr, 2021	"Identifying Risk and Preventing Cardiovascular Events in Patients with Psoriasis and Psoriatic Arthritis," NYU virtual webinar: Management of cardiometabolic risk in inflammatory conditions
Apr, 2021	"National Psoriasis Foundation COVID-19 Task Force," National Psoriasis Foundation Patient Meeting Webinar
Apr, 2021	"Psoriasis and cardiovascular risk: a model opportunity for prevention," NHLBI Prevention of Cardiovascular Disease in Patients with Psoriasis and Psoriatic Arthritis: Bridging the Evidence

	to Practice Gap for Statins Virtual Meeting
Apr, 2021	"Psoriasis Treatment Update: A Focus on Targeted Therapies," Interdisciplinary Autoimmune Summit 2021 Virtual Meeting
Apr, 2021	"Update on CV Risk in IMIDs," Interdisciplinary Autoimmune Summit 2021 Virtual Meeting
Apr, 2021	"COVID-19: IMID Updates," Interdisciplinary Autoimmune Summit 2021 Virtual Meeting
Jun, 2021	"Psoriasis assessment and treatment: A Primer for Dermatology Residents," University of Massachusetts, Worcester MA
Jun, 2021	"From Cardiovascular Disease to COVID-19: Implications for the management of psoriasis in 2021," University of Massachusetts, Worcester MA
Sep, 2021	"Management of Psoriasis During the COVID-19 Pandemic: Recommendations from the National Psoriasis Foundation COVID-19 Task Force," Dermatology Week, Virtual CME Meeting
Sep, 2021	"COVID-19 Update," National Psoriasis Foundation Town Hall
Oct, 2021	"Psoriasis, liver and cardiometabolic disease," Harvard Medical School CME program (virtual) for Central and Latin America
Oct, 2021	"Update on psoriasis: Keystone Dermatology 2021," Pennsylvania Society of Dermatology Physician Assistants, Annual Meeting, Philadelphia PA
Nov, 2021	"Key recommendations from the National Psoriasis Foundation COVID-19 Task Force for the Clinical Dermatologist," San Francisco Dermatology Society Annual Meeting
Nov, 2021	"Unmasking COVID19- An update on boosters," Healio virtual webinar
Dec, 2021	"Innovations in the management of psoriasis, Hackensack University Department of Medicine Grand Rounds
Jan, 2022	"Keeping up with Comorbidities and COVID19 in the Management of Psoriasis," Maui Derm, Maui Hawaii
Mar, 2022	"Risk of psoriasis treatment on COVID-19 infections and efficacy of COVID-19 vaccines," American Academy of Dermatology Annual Meeting, Boston, MA
Mar, 2022	"A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis (The VIP-A Trial)," American Academy of Dermatology Annual Meeting, Boston, MA
Mar, 2022	"New Developments in Psoriasis Comorbidity and COVID19," American Academy of Dermatology Annual Meeting, Boston, MA
Apr, 2022	"Immunologic Lessons from COVID-19 for IMID Care, Interdisciplinary Autoimmune Summit, Philadelphia, PA
Apr, 2022	"Cardiovascular Risk and Immune-Mediated Inflammatory Disorders," Interdisciplinary Autoimmune Summit, Philadelphia, PA
Apr, 2022	"JAK inhibitors in dermatology," Interdisciplinary Autoimmune Summit, Philadelphia, PA
May, 2022	"Frontiers in Dermatoepidemiology: Founders Award Lecture,"

- Society for Investigative Dermatology Annual Meeting, Portland, OR
- May, 2022 "Prevention of cardiovascular disease in patients with psoriasis or psoriatic arthritis (The CP3 study): Development and testing of a centralized care coordination model," Society for Investigative Dermatology Annual Meeting, Portland, OR
- May, 2022 "Getting Real (World) with Psoriasis: Advances in Registries and Real-World Data in Psoriasis", International Psoriasis Council at the Annual Meeting of the Society for Investigative Dermatology, Portland OR
- Jun, 2022 "The what, why, and how of pragmatic clinical trials" - Skin of Color Society Diversity in Clinical Trials, Washington, DC
- Jun, 2022 "Key updates in Psoriasis and Comorbidity" National Psoriasis Foundation Interdisciplinary Approaches to Holistic Care in Psoriatic Disease, Chicago, IL
- Jun, 2022 "Risk of psoriasis treatment on COVID-19 infections and efficacy of COVID-19 vaccines: A perspective from the United States" Best of AAD 2022 in China, Virtual Meeting

Organizing Roles in Scientific Meetings:

- May, 2008 Steering committee member, Society for Investigative Dermatology, Conference on Skin Disease Associated Co-morbidities Montreal, Canada
- Oct, 2008 Steering committee member, Society for Investigative Dermatology, Conference on Skin Disease Associated Co-morbidities Washington, DC
- Mar, 2009 Organizer, Forum on Drug Safety and Regulation, American Academy of Dermatology Annual Meeting San Francisco, CA
- May, 2009 Session Moderator, Epidemiology and Health Services Research, 69th Annual Meeting of the Society for Investigative Dermatology Montreal, Canada
- Mar, 2010 Session Director, Drug Safety Forum, American Academy of Dermatology, 68th Annual Meeting Miami, FL
- May, 2010 Steering committee member, Society for Investigative Dermatology, Conference on Co-morbidities Atlanta, GA
- Dec, 2010 Abstract review committee, GRAPPA International Meeting Miami, FL
- Feb, 2011 Session Director, Therapeutic Safety, American Academy of Dermatology, Annual Meeting New Orleans, LA
- May, 2011 Session Moderator, American Dermatoepidemiology Network Scientific Meeting, 74th Annual meeting of the Society for Investigative Dermatology

- Phoenix, AZ
 May, 2011 Session Moderator, Epidemiology and Health Services Research Symposium, 74th Annual meeting of the Society for Investigative Dermatology
- Phoenix, AZ
 May, 2011 Abstract Review Committee, Society of Investigative Dermatology, 2011 Annual Meeting
- Phoenix, AZ
 Jul, 2011 Abstract Review Committee, GRAPPA International Meeting
- Naples, Italy
 Mar, 2012 Session Director, Co-Morbidities in Dermatology, American Academy of Dermatology, Annual Meeting
- San Diego, CA
 May, 2012 Resident And fellows academic retreat organizer, Society for Investigative Dermatology
- Raleigh Durham
 May, 2012 American Dermatoepidemiology Network Session Moderator at the Society of Investigative Dermatology
- Raleigh, Durham
 Jun, 2012 GRAPPA annual meeting panel discussant and group moderator.
- Stockholm Sweden
 Nov, 2012 National Psoriasis Foundation research conference committee organizer
- Monterey, CA
 Mar, 2013 Symposium Director, Comorbidities in Dermatology, American Academy of Dermatology Annual Meeting
- Miami, FL
 Jul, 2013 Chair and Discussant, Plenary Session Specific aspects of psoriasis management, 4th Congress of the Psoriasis International Network
- Paris, France
 Mar, 2014 Symposium Director. Comorbidities in Dermatology. American Academy of Dermatology Annual Meeting
- Denver, Colorado.
 Mar, 2014 Session Moderator and Abstract Reviewer, Late breaking research. American Academy of Dermatology Annual Meeting
- Denver, Colorado
 May, 2014 Faculty Member, Resident's Retreat, Society for Investigative Dermatology
- Albuquerque, NM
 May, 2014 Faculty Member/Panelist, Junior Faculty Retreat, Society for Investigative Dermatology
- Albuquerque, NM
 Mar, 2015 Session Moderator and Abstract Reviewer, Late Breaking Research American Academy of Dermatology Annual Meeting
- San Francisco, CA
 Mar, 2015 Course Director, W019: Adverse Drug Reactions: The Evidence and

the Controversies, American Academy of Dermatology Annual Meeting
San Francisco, CA

May, 2015 Meeting Director, Resident and Fellow retreat at the Society for Investigative Dermatology Annual Meeting
Atlanta, GA

May, 2015 Meeting co-director, American Dermatoepidemiology Network Annual Meeting
Atlanta, GA

Jun, 2015 Co-Chair, Planning committee member, International Autoimmune Summit NACCME meeting
New York, NY

Mar, 2016 Course Director, F080: Adverse drug reactions: The evidence and the controversies. American Academy of Dermatology, Annual Meeting.
Washington, DC

Mar, 2016 Session moderator and abstract reviewer, Late Breaking Research American Academy of Dermatology, Annual Meeting.
Washington, DC

Apr, 2016 Co-Chair, Planning committee member, International Autoimmune Summit NACCME meeting
New York, NY

May, 2016 Session Moderator, ADEN. Society for Investigative Dermatology
Scottsdale, Arizona

May, 2016 Session Moderator, Clinical Epidemiology and Health Services Research.
Scottsdale, Arizona

Mar, 2017 Moderator late breaking research clinical trials, American Academy of Dermatology Annual Meeting
Orlando, FL

Mar, 2017 Director, Practical Approaches to Assessing Psoriasis and Psoriatic Arthritis Patients in Clinic, American Academy of Dermatology Annual Meeting
Orlando, FL

Aug, 2017 Discussion leader, National Psoriasis Foundation Scientific Meeting
Chicago, IL

Feb, 2018 Moderator, Late Breaking Clinical Trials Research, American Academy of Dermatology Annual Meeting
San Diego CA

Feb, 2018 Session Chair, F029 Practical approaches to assessing psoriasis and psoriatic arthritis patients in clinic. American Academy of Dermatology
San Diego, CA

Feb, 2018 "New Biologics for Patients with Psoriasis: An Oculus Virtual Reality View" Med Learning Group CME meeting
Miami, FL

- Apr, 2021 Meeting Organizer, NHLBI Prevention of Cardiovascular Disease in Patients with Psoriasis and Psoriatic Arthritis: Bridging the Evidence to Practice Gap for Statins
Virtual Meeting
- Nov, 2021 Session Moderator, Inflammatory Skin Disease Summit
New York, NY
- May, 2022 Meeting Organizer, Getting Real (World) with Psoriasis: Advances in Registries and Real-World Data in Psoriasis International Psoriasis Council at the Society for Investigative Dermatology Meeting
Portland, OR
- May, 2022 Session moderator, Clinical Research - Sociobehavioral and Health Services Research, Society for Investigative Dermatology Meeting
Portland, OR

Bibliography:

Research Publications, peer reviewed (print or other media):

1. Cochrane DE, Carraway RE, Feldberg RS, Boucher W, and Gelfand JM: Stimulated Rat Mast Cells Generate Histamine-Releasing Peptide from Albumin. Peptides 14: 117-123, 1993.
2. Arnsten JH, Gelfand JM, and Singer DE: Determinants of Compliance with Anticoagulation: A Case-Control Study. American Journal of Medicine 103: 11-17, 1997.
3. Gelfand JM, Rudikoff D, Lebwohl M, and Klotman ME: The Effect of Ultraviolet B Phototherapy on HIV-1 RNA Plasma Viral Level: A Prospective Self-Controlled Study. Archives of Dermatology 134: 940-945, 1998.
4. Schwartz E, Gelfand JM, Mauch JC, and Kligman LH: Modified Polyadenylation Site Selection in Tropoelastin mRNA Prepared from Sundamaged Human Skin and UV Treated Fibroblasts. Biochemical and Biophysical Research Communications 246: 217-221, 1998.
5. Gelfand JM, Hoffstad O, and Margolis DJ : Surrogate Endpoints for the Treatment of Venous Leg Ulcers. Journal of Investigative Dermatology 119: 1420-1425, 2002.
6. Gelfand JM, Berlin J, Van Voorhees A, and Margolis DJ: Lymphoma rates are low but increased in patients with psoriasis - results from a population based cohort study in the United Kingdom. Archives of Dermatology 139: 1425-9, 2003.
7. Lehrer M, Crawford G, Gelfand JM, Vittorio C, and Leyden JJ: The effect of wax epilation prior to hair removal with a long-pulsed alexandrite laser-a pilot study. Dermatologic Surgery 29: 118-23, 2003.
8. Margolis DJ, Gelfand JM, Hoffstad O, and Berlin JA: Surrogate endpoints for the

- treatment of diabetic neuropathic foot ulcers Diabetes Care 26: 1696-1700, 2003.
9. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, and Margolis DJ: Determinants of quality of life in patients with psoriasis: a study from the United States population. Journal of the American Academy of Dermatology 51: 704-708, 2004.
 10. Gelfand JM, Crawford G, Brod BA, and Szapary PO: Adverse cutaneous reactions to guggulipid: Results from a randomized, placebo controlled trial. Journal of the American Academy of Dermatology 52: 533-4, 2005.
 11. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, and Rolstad T: Epidemiology of Psoriatic Arthritis in the United States Population. Journal of the American Academy of Dermatology 53: 573-7, 2005.
 12. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, and Margolis DJ: The prevalence of psoriasis in African Americans: Results from a population based study. Journal of the American Academy of Dermatology 52: 23-6, 2005.
 13. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, and Margolis DJ: Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Archives of Dermatology 141: 1537-1541, 2005.
 14. Gupta G, Gelfand JM, and Lewis JD: Increased Risk of Demyelinating Diseases in Patients with Inflammatory Bowel Disease. Gastroenterology 129(3): 819-826, 2005.
 15. Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, and Rook AH: Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome. Journal of the American Academy of Dermatology 53(3): 428-34, 2005.
 16. Nijsten T, Whalley D, Gelfand JM, Margolis DJ, McKenna S, and Stern RS: The psychometric qualities of the Psoriasis Disability Index in the United States Population. Journal of Investigative Dermatology 125: 665-72, 2005.
 17. Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, Gelfand JM, Lessin S, and Seykora JT: Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. Journal of Cutaneous Pathology 32: 125-130, 2005.
 18. Brown TT, Quain RD, Troxel AB, and Gelfand JM: The epidemiology of sunburn in the U.S. population in 2003. Journal of the American Academy of Dermatology 55: 577-83, 2006.

19. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, and Troxel AB: The risk of myocardial infarction in patients with psoriasis. Journal of the American Medical Association 296: 1735-1741, 2006.
20. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, and Troxel AB: The risk of lymphoma in patients with psoriasis. Journal of Investigative Dermatology 126: 2194-2201, 2006.
21. Neimann AL, Hodinka RL, Joshi YB, Elkan M, Van Voorhees AS, and Gelfand JM: Epstein-Barr-virus and human herpesvirus type 6 infection in patients with Psoriasis. European Journal of Dermatology 16: 548-52, 2006.
22. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB and Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. Journal of the American Academy of Dermatology 55: 829-35, 2006.
23. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, and Strom BL: The risk of mortality in patients with psoriasis: Results from a population-based study. Archives of Dermatology 143: 1493-1498, 2007.
24. Li W, Marshall C, Mei L, Gelfand J, and Seykora JT: Srcasm corrects Fyn-induced epidermal hyperplasia by kinase downregulation. The Journal of Biological Chemistry 282: 1161-9, 2007.
25. Nijsten T, Meads DM, de Korte J, Sampogna F, Gelfand JM, Ongenaes K, Evers AW, and Augustin M: Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. Journal of Investigative Dermatology 127: 2315-22, 2007.
26. Pulitzer M, Li W, Hanson M, Singh F, Elenitsas R, Gelfand JM, VanVoorhees A and Seykora JT: Srcasm overexpression in psoriasis-insights into pathogenesis. Journal of Cutaneous Pathology 34: 160-5, 2007.
27. Wysoka M, Newton S, Benoit BM, Introcoso C, Hancock AS, Chehimi J, Richardson SK, Gelfand JM, Montaner LJ, and Rook AH: Synthetic imidazoquinolines potently and broadly activate the cellular immune response of cutaneous T-cell lymphoma patients: Synergy with IFN- gamma enhances production of IL-12. Clinical Lymphoma and Myeloma 7: 524-534, 2007.
28. Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, and Strom BL: Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease. American Journal of Gastroenterology 103(6): 1428-35; quiz 1436, June 2008.
29. Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, Freundlich B and

- Stevens SR: Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with Etanercept: Continuous versus interrupted treatment. Value in Health 11: 400-7, 2008.
30. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, and Gelfand JM: Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. Journal of the American Academy of Dermatology 58: 625-31, 2008.
31. Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J and Gelfand JM: Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. Journal of Drugs in Dermatology 7: 1137-1146, 2008.
32. Suh L, Coffin S, Leckerman KH, Gelfand JM, Honig PJ, and Yan AC: Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis. Pediatric Dermatology 25: 528-534, 2008.
33. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, Shin DB, Leyden JJ, Vittorio C and Gelfand JM: A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. Journal of the American Academy of Dermatology 60(4): 565-73, April 2009.
34. Gelfand JM, Dommasch E, Shin DB, Azfar RS, Kurd SK, Wang X, and Troxel AB: The Risk of Stroke in Patients with Psoriasis. Journal of Investigative Dermatology 129: 2411-2418, 2009.
35. Jambusaria-Pahlajani A, Schmults CD, Miller M, Shin D, Williams J, Kurd SK, and Gelfand, JM: Utility of High Frequency Ultrasound in the Pre-Operative Assessment of Margins of Basal Cell and Squamous Cell Carcinoma Dermatologic Surgery 35: 9-15, 2009.
36. Kurd SK and Gelfand JM: The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004. Journal of the American Academy of Dermatology 60: 218-224, 2009.
37. Morganroth PA, Gelfand JM, Jambusaria A, Margolis DJ, and Miller CJ: A randomized, double-blind comparison of the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine required for effective local anesthesia during Mohs surgery for skin cancers. Journal of the American Academy of Dermatology 60: 444-452, 2009.
38. Smith N, Shin DB, Brauer JA, Mao J, and Gelfand JM: Use of complementary and alternative medicine (CAM) among adults with skin disease: results from a national survey. Journal of the American Academy of Dermatology 60: 419-425, 2009.

39. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, and Gelfand JM: Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the United Kingdom. British Journal of Dermatology 163(3): 449, September 2010.
40. Ayli E, Dugas-Breit S, Li W, Marshall C, Zhao L, Griffin T, Meulener M, Gelfand JM, and Seykora JT: Curcuminoid activate P38 Map Kinases and promote UVB-Dependent signaling in keratinocytes. Experimental Dermatology 146: 891-5, 2010.
41. Dommasch E, Shin DB, Troxel AB, Margolis DJ, and Gelfand JM: Reliability, Validity, and Responsiveness to Change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for Measuring Body Surface Area Affected by Psoriasis. British Journal of Dermatology 162: 825-42, 2010.
42. Kimball, AB, Pariser, D, Yamauchi, PS, Menter, A, Teller, CF, Shi, Y, Creamer, K, McCroskery, P, Kricorian, G, and Gelfand, JM: Observe-5, an Observational Post-marketing Safety surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. Psoriasis Forum 16: 3-7, 2010.
43. Kurd, SK, Troxel AB, Crits-Christoph P and Gelfand JM: The risk of depression, anxiety and suicidality in patients with psoriasis: A population-based cohort study. Archives of Dermatology 146: 891-5, 2010.
44. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, and Gelfand JM: Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using General Practice Research Database. European Heart Journal 31: 1000-06, 2010.
45. Seminara N, Abuabara K, Langan S, Shin DB, Kimmel S, Margolis DJ, Troxel AB, and Gelfand JM: Validity of The Health Improvement Network (THIN) for the study of psoriasis. British Journal of Dermatology 164(3): 602-609, March 2011.
46. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, and Choi HK: Prevalence of the metabolic syndrome in psoriasis: Results from the NHANES study 2003-2006. Archives of Dermatology 147(4): 419-424, April 2011.
47. Dommasch, ED, Abuabara, K, Shin, DB, Nguyen, J, Troxel, AB, and Gelfand JM. : The Risk of Infection and Malignancy with Tumor Necrosis Factor Antagonists in Adult Patients with Psoriatic Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of the American Academy of Dermatology 64(6): 1035-1060, June 2011.
48. Azfar RA, Weinberg JL, Cavric G, Lee-Keltner IA, Bilker WB, Gelfand JM, and

- Kovarik CL: HIV-positive patients in Botswana state that mobile teledermatology is an acceptable method for receiving dermatology care. Journal of Telemedicine and Telecare 17(6): 338-340, August 2011.
49. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy, P, Shin DB, Troxel AB, and Gelfand JM: Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events. American Journal of Medicine 124(8): 775 e. 1-6, August 2011.
50. Mehta N, Yu YD, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, and Gelfand JM: Systemic and Vascular Inflammation in Patients with Moderate to Severe Psoriasis as measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT): A Pilot Study. Archives of Dermatology 147(9): 1031-1039, September 2011.
51. Wysocka M, Dawany N, Benoit B, Kossenkov AV, Troxel AB, Gelfand JM, Sell MK, Showe LC, and Rook AH: Synergistic Enhancement of Cellular Immune Responses by the Novel Toll Receptor 7/8 Agonist 3M 007 and Interferon- γ : Implications for Therapy of Cutaneous T-Cell Lymphoma. Leukemia and Lymphoma 52(10): 1970-1979, October 2011.
52. Langan SM, Seminara, NM, Shin, DB, Troxel A, Kimmel SE, Mehta NN, Margolis DJ, and Gelfand JM: Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. Journal of Investigative Dermatology Advance Online Publication, November 2011.
53. Wan J, Abuabara K, Kurd KK, Musiek A, Steinemann JM, Vittorio CC, and Gelfand JM: Reliability and validity of a photographic method for measuring facial hair density in males. Archives of Dermatology 147(11): 1328-1329, November 2011.
54. Raphael BA, Shin DB, Suchin KR, Morrissey KA, Vittorio CC, Kim EJ, Gardner JM, Evans KG, Introcaso CE, Gelfand JM, Rook AH: High clinical response rate of Sézary syndrome with immune modifying therapies: prognostic markers of response. Archives of Dermatology 147(12): 1410-1415, December 2011.
55. Wan J, Abuabara K, Shin DB, Troxel AB, Bebo BF, and Gelfand JM: Dermatologist Response Rates to a Mailed Questionnaire: A Randomized Trial of Monetary Incentives. Journal of the American Academy of Dermatology 66(1): e18-20, January 2012.
56. Wan J*, Vittorio CC*, Abuabara K, Kurd SK, Musiek A, Steinemann JM, and Gelfand JM: A randomized, double-blind, placebo-controlled proof of concept trial of topical 1% and 3% cidofovir for the prevention of beard hair growth in males. Archives of Dermatology 148(2): 257-259, February 2012 Notes:
*Co-first authors contributing equally

57. Wan J, Abuabara K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF, Krueger GG, Callis Duffin K, and Gelfand JM: Dermatologist preferences for first-line therapy of moderate-to-severe psoriasis in healthy adult patients. Journal of the American Academy of Dermatology 66(3): 376-386, March 2012.
58. Gelfand JM, Wan J, Callis Duffin, K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, and Van Voorhees AS: Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting. Archives of Dermatology 148(4): 487-94, April 2012.
59. Azfar AS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, and Gelfand JM: Increased Risk of Diabetes and Likelihood of Receiving Diabetes Treatment in Patients with Psoriasis. Archives of Dermatology 18: 1 - 6 Jun 2012.
60. Arkin LM, Flory JH, Shin DB, Gelfand JM, Treat JR, Allen J, Rubenstein RC, and Yan AC: High Prevalence of Aquagenic Wrinkling of the Palms in Patients with Cystic Fibrosis and Association with Measurable Increases in Transepidermal Water Loss. Pediatric Dermatology Page: doi: 10.1111/j.1525-1470.2011.01708.x, 2012.
61. Kimball AB, Kerdel F, Adams D, Mroweitz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, Van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, and Jemec GBE.: Efficacy and safety of adalimumab in the treatment of moderate to severe hidradenitis suppurativa: A randomized controlled trial. Annals of Internal Medicine 157: 846-55, 2012.
62. Love JT, Zhu Y, Wall Burns L, Ogdie A, Gelfand JM, and Choi HK.: Obesity and risk of psoriatic arthritis: a population based-study. Ann Rheum Dis 2012 71: 1273-7, 2012.
63. Mehta NN, Krishnamoorthy P, Yu Y, Khan O, Raper A, Van Voorhees A, Troxel AB and Gelfand JM.: "The impact of psoriasis on 10-year Framingham risk." Journal of American Academy of Dermatology 67: 796-8, 2012.
64. Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodriguez A, Raper A, Wilcox M, Baer A, DerOhannesian S, Wolfe M, Reilly MP, Rader DJ, Van Voorhees A, Gelfand JM: Abnormal Lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis (224), 218-21, 2012.
65. Mehta NN, Torigian DA, Gelfand, JM, Saboury, B, and Alavi A: Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT). Journal of Visualized Experiments 63: e3777, 2012.

66. Wan J, Abuabara, K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF, Kruger GG, Callis Duffin K, and Gelfand JM: Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate-to-severe psoriasis. Archives of Dermatology 148: 539- 540, 2012.
67. Yu,Y; Sheth,N; Krishnamoorthy,P; Saboury,B; Baer,A; Ochotony,R; Dovekis,J; Derohannessian,S; VanVoorhees, AS; Torigian, DA; Alavi, A; Gelfand, JM; Mehta, NN.: "Aortic vacular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study." Am J cardiovascular Diseases 2(4): 285-92, 2012.
68. Jambusaria-Pahlajani A, Kanetsky PA, Karia PA, Hwang WT, Gelfand JM, Whalen FM, Elenitsas R, Xu X, Schmults CD: Evaluation of AJCC tumor staging for cutaneous squamos cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatology 16: 1-9, Jan 2013.
69. Li RC, Krishnamoorthy P, DerOhannessian S, Doveikis J, Wilcox M, Thomas P, Rader DJ, Reilly MP, Van Voorhees A, Gelfand JM, Mehta NN: Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol 39(1): 19-24, January 2013.
70. Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, Mehta N, Troxel A, Choi H, Gelfand JM.: Prevalence and treatment patterns of psoriatic arthritis in United Kingdom. Rheumatology 52(3): 568-75, Mar 2013.
71. Asagri MM, Wu JJ, Gelfand, JM, Salman C, Curtis JR, Harrold LR, Herrinton JJ.: Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population. Pharmacoepidemiol Drug Saf. May 2013 Notes: doi: 10.1002/pds.3447 [Epub ahead of print]
72. Kimball AB, Pariser D, Yamauchi PS, Menter A, Teller CF, Shi Y, Yong M, Creamer K, Hooper M, Aras G, Kricorian G, and Gelfand JM: "Observe -5 Interim Analysis:An observational safety registry of etanercept for the treatment of psoriasis." Journal of the American Academy of Dermatology 68(5): 756-64, May 2013.
73. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, and Gelfand JM.: The risk of moderate to advanced kidney disease in patients with psoriasis: a population-based cohort study. British Medical Journal 15: 347:593, October 2013.
74. Callis Duffin K, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, Shin DB, Van Voorhees A, Gelfand JM: Patient Satisfaction with Treatments for Moderate-to-Severe Plaque Psoriasis in Clinical Practice. BR J Dermatol 22, November 2013 Notes: doi: 10.1111/bjd.12745.

75. Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF, Kreuger GG, Callis Duffin K, and Gelfand JM.: Variations in dermatologist beliefs about the safety and effectiveness of treatments for moderate-to-severe psoriasis. Journal of American Academy of Dermatology 68: 262-9, 2013.
76. Harrold LR, Slaman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM, Wu JJ, Herrinton LJ: Incidence and prevalence of Juvenile Idiopathic Arthritis among children in a managed care population, 1996-2009. J of Rheumatology 40: 1218-1225, 2013.
77. Rose S, Sheth NH, Baker JF, Ogdie A, Raper A, Saboury B, Werner JT, Thomas R, Van Voorhees A, Alavi A, Torigian DA, Gelfand JM, and Mehta NN: A Comparison of Vascular Inflammation in Psoriasis, Rheumatoid Arthritis, and Healthy Subjects by FDG-PET/CT: A Pilot Study. AM J Cardiovasc Dis. 3(4): 273-278, 2013.
78. Rosenbach M*, Yeung H*, Chu EY, Kim EJ, Payne AS, Takeshita J, Vittorio CC, Wanat KA, Werth VP, Gelfand JM: Reliability and convergent validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for assessing cutaneous sarcoidosis. JAMA Dermatology 149: 550-6, 2013.
79. Walsh JA, McFadden M, Woodcock J, Clegg DO, Dommasch E, Gelfand JM, Kruger, GG, Callis Duffin K.: Product of the physician global assessment and body surface area (PGAxBSA): a simple static measure of psoriasis severity in a longitudinal cohort. Journal of the American Academy of Dermatology 2013 69(6): 931-7, December 2013.
80. Yeung H, Takeshita T, Mehta NN, Kimmel Se, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM: Psoriasis severity and the prevalence of major medical co-morbidities: a population based study. JAMA Dermatology 149: 1173-9, 2013.
81. Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Kreuger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Bebo F, Schleicher SM, Shin DB, Troxel AB, and Gelfand JM.: "Patient reported reasons for the discontinuation of commonly used treatments for moderate-to-severe psoriasis." Journal of American Academy of Dermatology 68: 64-72, 2013.
82. Ogdie A, Haynes K, Troxel AB, Love TJ, Hennessy S, Choi H, and Gelfand JM: Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis, and psoriasis: a longitudinal cohort study. Ann Rheum Disease 73(1): 149-53, January 2014.
83. Dubreuil M, Rho YH, Man A, Zhu Y, Zhang Y, Love TJ, Ogdie A, Gelfand JM, and Choi HK.: The Independent Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Diabetes Incidence: A UK Population-Based Cohort Study. Rheumatology (Oxford) 53(2): 346-52, February 2014.

84. Takeshita J, Mohler ER, Krishnamoorthy P, Moore J, Rogers WT, Zhang L, Gelfand JM, Mehta NN.: Endothelial cell-platelet- and monocyte/macrophage microparticles are elevated in psoriasis beyond cardiovascular risk factors. J. Am Heart Assoc 3(1): 28, February 2014 Notes: doi: 10.1161/JAHA.113.00507.
85. Azfar RS, Lee RA, Castelo-Soccio L, Greenberg MS, Bilker WB, Gelfand JM, Kovarik CL.: Reliability and validity of mobile teledermatology in Human Immunodeficiency Virus-Positive patients in Botswana: A Pilot Study. JAMA Dermatology 150(6): 601-7, June 2014.
86. Ogdie O, Alehashemi S, Love TJ, Jiang Y, Haynes K, Hennessy S, Choi H, Gelfand JM.: Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the Health Improvement Network. Pharmacoepidemiology and Drug Safety 23(9): 918-22, September 2014.
87. Takeshita, J., Wang, S., Shin, D.B., Callis Duffin, K., Krueger, G.G., Kalb, R.E., Weisman, J.D., Sperber, B.R., Stierstorfer, M.B., Brod, B.A., Schleicher, S.M., Robertson, A.D., Linn, K.A., Shinohara, R.T., Troxel, A.B., Van Voorhees, A.S., Gelfand, J.M.: Effectiveness of Less Commonly Used Systemic Monotherapies and Common Combination Therapies for Moderate-to-Severe Psoriasis in the Clinical Setting. Journal of the American Academy of Dermatology Sept 2014 Notes: pii: S0190-9622(14)01794-0. doi: 10.1016/j.jaad.2014.08.003.
88. Chu D, Castelo-Soccio L, Wan J, Gelfand JM, Shaddy D, Shah K, Permen M, Treat J, and Yan A.: "Retrospective Analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT Study). Clinical Pediatrics 53(11): 1084-90, Oct 2014.
89. Chung J, Callis Duffin K, Takeshita J, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Edson-Heredia E, and Gelfand JM: Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared to moderate to severe plaque psoriasis. J Amer Acad Dermatol 71(4): 623-32, Oct 2014.
90. Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, and Gelfand JM: Patient-reported outcomes in psoriasis patients with clear versus almost clear skin in the clinical setting. Journal of the American Academy of Dermatology 71(4): 633-41, Oct 2014.
91. Abuabara K, Hoffstad O, Troxel A, Gelfand JM, and Margolis DJ: Atopic dermatitis disease control and age: a cohort study. Journal of Allergy and Clinical Immunology 136(1): 190-192, Jul 2015.
92. Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, Viswanathan HN, Doshi JA: Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. J Invest Dermatol Jul 2015 Notes: doi:

10.1038/jid.2015.296. [Epub ahead of print]

93. Bakshi A, Gholami S, Alavi A, Gelfand JM, Takeshita J: Assessing Cutaneous Psoriasis Activity Using FDG-PET: Nonattenuation Corrected Versus Attenuation Corrected PET Images. Clin Nucl Medicine 2015 40(9): 727-9, Sep 2015.
94. Rook AH, Gelfand JM, Wysocka M, Troxel AB, Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R, Kirsch IR, Kim EJ, Clark RA: Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 126(12): 1452-61, Sep 2015.
95. Chiesa Fuxench ZC, Callis Duffin K, Siegel M, Van Voorhees AS, Gelfand JM: Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis. J Am Acad Dermatol 73(5): 868-70, Nov 2015.
96. Kimball AB, Rothman KJ, Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand : OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol.(72), 115-22, 2015.
97. Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T, Ng Q, Joshi AA, Krishnamoorthy P, Dave J, Rose SM, Doveikis J, Playford MP, Prussick RB, Ehrlich A, Kaplan MJ, Lockshin BN, Gelfand JM, Mehta NN: Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study. Arterioscler Thromb Vasc Biol 35(12): 2667-76, Dec 2015 Notes: pii: ATVBAHA.115.306460.
98. Ogdie A, YiDing Y, Haynes K, Love JL, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi H, Mehta NN, and Gelfand JM: Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A population-based cohort study. Annals of Rheumatology. Annals of Rheumatology(74), 326-22, 2015.
99. Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, Troxel AB, and Gelfand JM.: Impact of psoriasis severity on hypertension control: A population-based study in the United Kingdom. JAMA Dermatology(151), 161-9, 2015.
100. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM: The Risk of Cancer in Patients with Psoriasis: A population-based cohort study in The Health Improvement Network. JAMA Dermatology 52(3): 282-90, March 2016.
101. Doshi JA, Takeshita J, Pinto L, Li P, Yu X, Rao P, Viswanathan HN, Gelfand JM :

- Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol March 2016 Notes: pii: S0190-9622(16)00128-6. doi: 10.1016/j.jaad.2016.01.048.
102. Etzkorn JR, Sobanko JF, Shin TM, Elenitsas R, Chu EY, Gelfand JM, Margolis DJ, Newman JG, Goldbach H, Miller CJ: Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery With Melanoma Antigen Recognized by T Cells 1 Immunostaining. Dermatol Surg 42(4): 471-6, April 2016.
103. Curtis JR, Harrold LR, Asgari MM, Deodhar A, Salman C, Gelfand JM, Wu JJ, Herrinton LJ: Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. Perm J 20(4), July 2016 Notes: doi: 10.7812/TPP/15-151. [Epub ahead of print]
104. Aberra TM, Joshi AA, Lerman JB, Rodante JA, Dahiya AK, Teague HL, Ng Q, Silverman JI, Sorokin AV, Salahuddin T, Lockshin BN, Ahlman MA, Playford MP, Chen MY, Gelfand JM, Mehta NN: Self-reported depression in psoriasis is associated with subclinical vascular diseases. Atherosclerosis Page: 219-25, Aug 2016.
105. Aberra TM, Joshi AA, Lerman JB, Rodante JA, Dahiya AK, Teague HL, Ng Q, Silverman JI, Sorokin AV, Salahuddin T, Lockshin BN, Ahlman MA, Playford MP, Chen MY, Gelfand JM, Mehta NN.: Self-reported depression in psoriasis is associated with subclinical vascular diseases. Atherosclerosis 251: 219-25, August 2016 Notes: doi: 10.1016/j.atherosclerosis.2016.05.043.
106. Chiesa Fuxench ZC, Troxel AB, Gelfand JM: Validity of diagnosis codes for identifying cutaneous squamous cell carcinoma in The Health Improvement Network. Br J Dermatol August 2016 Notes: doi: 10.1111/bjd.14957.
107. Grewal SK, Wan J, Denburg MR, Shin DB, Takeshita J, Gelfand JM: The risk of IgA nephropathy and glomerular disease in patients with psoriasis: A population based cohort study. Br J Dermatol. August 2016 Notes: doi: 10.1111/bjd.14961. [Epub ahead of print]
108. Joshi AA, Lerman JB, Aberra TM, Afshar M, Teague HL, Rodante JA, Krishnamoorthy P, Ng Q, Aridi TZ, Salahuddin T, Natarajan B, Lockshin BN, Ahlman MA, Chen MY, Rader DJ, Reilly M, Remaley AT, Bluemke DA, Playford MP, Gelfand JM, Mehta NN: GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. Circ Res. September 2016 Notes: pii: CIRCRESAHA.116.309637.
109. Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A.: The Incidence and Management

- of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. Arthritis Care Res (Hoboken) 1, October 2016 Notes: doi: 10.1002/acr.23094. [Epub ahead of print]
110. Herrinton LJ, Harrold L, Salman C, Liu L, Goldfien R, Asgari M, Gelfand JM, Wu JJ, Curtis JR : Population Variations in rheumatoid arthritis treatment and outcomes, Northern California, 1998-2009. Permanente Journal 20(1): 4-12, 2016.
111. M Augustin, S Abeysinghe, U Mallya, A Qureshi, N Roskell, D McBride, C Papavassillis, JM Gelfand: Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response-results of a phase II regimenâ€• finding trial. Journal of the European Academy of Dermatology and Venereology 30: 645-49, 2016.
112. Dunbar RL, Goel H, Tuteja S, Song WL, Nathanson G, Babar Z, Lalic D, Gelfand JM, Rader DJ, Grove GL : Measuring Physical Stigmata of Niacin-Associated Skin Toxicity by Colorimetry, White-Light Spectroscopy, Laser Doppler Flowmetry, and Thermometry in Combination with Symptom Perception Scoring: Methods to Aid Development of Niacin Mimetics. J Lipid Res Jan 2017 Notes: pii: jlr.D071696. doi: 10.1194/jlr.D071696.
113. Shin TM, Etzkorn JR, Sobanko JF, Margolis DJ, Gelfand JM, Chu EY, Elenitsas R, Shaikh WR, Miller CJ: Clinical factors associated with subclinical spread of in situ melanoma. J Am Acad Dermatol Jan 2017 Notes: pii: S0190-9622(16)31162-8.
114. Thorarensen SM, Lu N, Ogdie A, Gelfand JM, Choi HK, Love TJ.: Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis 76(3): 521-525, March 2017 Notes: annrheumdis-2016-209334. doi: 10.1136/annrheumdis-2016-209334. [Epub ahead of print]
115. Ogdie A, McGill NK, Shin DB, Takeshita J, Love TJ, Noe M, Chiesa Fuxench Z, Choi HK, Mehta NN, and Gelfand JM: Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis, and rheumatoid arthritis: A General Population-Based Cohort Study. European Heart Journal Apr 2017 Notes: doi: 10.1093/eurheartj/ehx145.
116. Shin TM, Shaikh WR, Etzkorn JR, Sobanko JF, Margolis DJ, Gelfand JM, Chu EY, Elenitsas R, Miller CJ: Clinical and pathologic factors associated with subclinical spread of invasive melanoma. J Am Acad Dermatol 76(4): 714-21, April 2017 Notes: pii: S0190-9622(16)31165-3.
117. Ogdie A, Harter L, Shin D, Baker J, Takeshita J, Choi HK, Love TJ, Gelfand JM: The risk of fracture among patients with psoriatic arthritis and psoriasis: a

- population-based study. Ann Rheum Dis 76(5): 882-885, May 2017 Notes: pii: annrheumdis-2016-210441.
118. Abuabara K, Hoffstad O, Troxel AB, Gelfand JM, McCulloch CE, Margolis DJ: Patterns and predictors of atopic dermatitis disease control past childhood: An observational cohort study. J Allergy Clin Immunol 141(2): 778-780, Jun 2017 Notes: doi: 10.1016/j.jaci.2017.05.031. Epub 2017 Jun 17. No abstract available.
119. Ogdie A, Maliha S, Shin D, Love TJ, Baker J, Jiang Y, Choi H, Gelfand JM: Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. Rheumatology 56(6): 907-911, Jun 2017 Notes: doi: 10.1093/rheumatology/kew502.
120. Abuabara K, Magyari AM, Hoffstad O, Jabbar-Lopez ZK, Smeeth L, Williams HC, Gelfand JM, Margolis DJ, Langan SM: Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK. J Invest Dermatol 137(8): 1655-1662, Aug 2017 Notes: doi: 10.1016/j.jid.2017.03.029. Epub 2017 Apr 18.
121. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM: Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol 77(2): 274-279, Aug 2017 Notes: e3. doi: 10.1016/j.jaad.2017.04.019. Epub 2017 Jun 9.
122. Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, Teague HL, Harrington CL, Rivers JP, Chung JH, Kabbany MT, Natarajan B, Silverman JI, Ng Q, Sanda GE, Sorokin AV, Baumer Y, Gerson E, Prussick RB, Ehrlich A, Green LJ, Lockshin BN, Ahlman MA, Playford MP, Gelfand JM, Mehta NN: Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. JAMA Cardiol 2(9): 1013-1018, Sept 2017 Notes: doi: 10.1001/jamacardio.2017.1213.
123. Wan MT, Strober BE, Wu JJ, Shin DB, Gelfand JM: How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials. J Am Acad Dermatol 77(3): 569-572, Sept 2017 Notes: doi: 10.1016/j.jaad.2017.05.032. Review.
124. Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ, Rodante J, Lerman JB, Ahlman MA, Gelfand JM, Mehta NN: The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol 77(4): 650-656, Oct 2017 Notes: doi: 10.1016/j.jaad.2017.06.028. Epub 2017 Aug 18.
125. Noe MH, Grewal SK, Shin DB, Ogdie A, Takeshita J, Gelfand JM: Increased

- prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom. J Eur Acad Dermatol Venereol Page: 1674-1680, Oct 2017 Notes: doi: 10.1111/jdv.14310. Epub 2017 Jun 1.
126. Ogdie A, Grewal SK, Noe MH, Shin D, Takeshita J, Chiesa Fuxench ZC, Carr RM, Gelfand JM: Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Invest Dermatol Oct 2017 Notes: pii: S0022-202X(17)33097-X. doi: 10.1016/j.jid.2017.10.024. [Epub ahead of print]
127. Wan J, Mitra N, Hoffstad OJ, Gelfand JM, Yan AC, Margolis DJ: Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study. J Am Acad Dermatol 77(4): 634-640, Oct 2017 Notes: doi: 10.1016/j.jaad.2017.06.013. Epub 2017 Aug 14.
128. Baumer Y, Ng Q, Sanda GE, Dey AK, Teague HL, Sorokin AV, Dagur PK, Silverman JI, Harrington CL, Rodante JA, Rose SM, Varghese NJ, Belur AD, Goyal A, Gelfand JM, Springer DA, Bleck CK, Thomas CL, Yu ZX, Winge MC, Kruth HS, Marinkovich MP, Joshi AA, Playford MP, Mehta NN: Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. JCI Insight 11(3), Jan 2018 Notes: pii: 97179. doi: 10.1172/jci.insight.97179. [Epub ahead of print]
129. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM: The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 78(1): 54-61, Jan 2018 Notes: e1. doi: 10.1016/j.jaad.2017.08.002. Epub 2017 Oct 7.
130. Fischer AH, Shin DB, Gelfand JM, Takeshita J: Health care utilization for psoriasis in the United States differs by race: An analysis of the 2001-2013 Medical Expenditure Panel Surveys. J Am Acad Dermatol 78(1): 200-203, Jan 2018 Notes: doi: 10.1016/j.jaad.2017.07.052.
131. Nguyen UDT, Zhang Y, Lu N, Louie-Gao Q, Niu J, Ogdie A, Gelfand JM, LaValley MP, Dubreuil M, Sparks JA, Karlson EW, Choi HK: Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Ann Rheum Dis 77(1): 119-123, Jan 2018 Notes: doi: 10.1136/annrheumdis-2017-211625. Epub 2017 Nov 4.
132. Rivers JP, Powell-Wiley TM, Dey AK, Rodante JA, Chung JH, Joshi AA, Natarajan B, Sajja AP, Chaturvedi A, Rana A, Harrington CL, Teague HL, Lockshin BN, Ahlman MA, Yao J, Playford MP, Gelfand JM, Mehta NN: Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study. JACC Cardiovasc Imaging 2 PT 2: 349-357, Feb 2018 Notes: doi: 10.1016/j.jcmg.2017.08.014.

Epub 2017 Oct 18.

133. Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM: Psoriasis and the risk of diabetes: A prospective population-based cohort study. J Am Acad Dermatol 78(2): 315-22, Feb 2018.
134. Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, Hubbard RA, Kalb RE, Menter A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tyring SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM: Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial Circ Cardiovasc Imaging 11(6): e007394, Jun 2018 Notes: doi: 10.1161/CIRCIMAGING.117.007394.
135. Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, Boggs J, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Gordon S, Hamrick R, Ho B, Hughey LC, Jones LM, Kaffenberger BH, Kindley K, Kroshinsky D, Kwong BY, Miller DD, Mostaghimi A, Musiek A, Ortega-Loayza AG, Patel R, Posligua A, Rani M, Saluja S, Sharon VR, Shinkai K, John JS, Strickland N, Sun N, Wanat KA, Wetter DA, Worswick S, Yang C, Margolis DJ, Gelfand JM, Rosenbach M: Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol 18: S0022-202X, Jul 2018.
136. Pearl RL, Wan MT, Takeshita J, Gelfand JM: Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students. J Am Acad Dermatol Aug 2018 Notes: Epub ahead of print.
137. Sobanko JF¹, Dai J², Gelfand JM³, Sarwer DB⁴, Percec I: Prospective Cohort Study Investigating Changes in Body Image, Quality of Life, and Self-Esteem Following Minimally Invasive Cosmetic Procedures. Dermatol Surg 8(44): 1121-28, Aug 2018.
138. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Chiesa Fuxench ZC: Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol 121(3): 340-47, Sept 2018.
139. Armstrong AW, Chambers CJ, Maverakis E, Cheng MY, Dunnick CA, Chren MM, Gelfand JM, Wong DJ, Gibbons BM, Gibbons CM, Torres J, Steel AC, Wang EA, Clark CM, Singh S, Kornmehl HA, Wilken R, Florek AG, Ford AR, Ma C, Ehsani-Chimeh N, Boddu S, Fujita M, Young PM, Rivas-Sanchez C, Cornejo BI, Serna LC, Carlson ER, Lane CJ: Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. JAMA Netw Open 1(6), Oct 2018.

140. Joshi AA, Lerman JB, Dey AK, Sajja AP, Belur AD, Elnabawi YA, Rodante JA, Abera TM, Chung J, Salahuddin T, Natarajan B, Dave J, Goyal A, Groenendyk JW, Rivers JP, Baumer Y, Teague HL, Playford MP, Bluemke DA, Ahlman MA, Chen MY, Gelfand JM, Mehta NN: Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis. JAMA Cardiol 3(10): 949-56, Oct 2018.
141. Silverberg JI, Gelfand JM, Margolis D, Fonacier L, Boguniewicz M, Schwartz LB, Simpson EL, Grayson M, Ong PY, Chiesa Fuxench ZC: Severity strata for POEM, PO-SCORAD and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol 121(4): 464-71, Oct 2018.
142. Armstrong AW, Ford AR, Chambers CJ, Maverakis E, Dunnick CA, Chren MM, Gelfand JM, Gibbons CM, Gibbons BM, Lane CJ: Online Care Versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial. J Invest Dermatol Nov 2018 Notes: Epub ahead of print.
143. Barbieri JS, Gelfand JM: Evaluation of the Dermatology Life Quality Index scoring modification, the DLQI-R score, in two independent populations. Br J Dermatol Nov 2018 Notes: Epub ahead of print.
144. Silverberg JI, Gelfand JM, Margolis D, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong P, Chiesa Fuxench ZC: Association of atopic dermatitis with allergic, autoimmune and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol 121(5): 604-12, Nov 2018.
145. Sorokin AV, Kotani K, Elnabawi YA, Dey AK, Sajja AP, Yamada S, Ueda M, Harrington CL, Baumer Y, Rodante JA, Gelfand JM, Chen MY, Joshi AA, Playford MP, Remaley AT, Mehta NN: Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis. Circ Res 123(11): 1244-54, Nov 2018.
146. Silverberg JI, Chiesa Fuxench ZC, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY: Content and construct validity, predictors and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol 121(6): 729-34, Dec 2018.
147. Wan MT, Alvarez J, Shin DB, Dommasch ED, Wu JJ, Gelfand JM: Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. J Eur Acad Dermatol Venereol 33(1): 42-55, Jan 2019.
148. Noe MH, Shin DB, Hubbard RA, Hennessy S, Gelfand JM: Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases. J Invest Dermatol 139(2): 473-75, Feb 2019.

149. Takeshita J, Eriksen WT, Raziano VT, Bocage C, Hur L, Shah RV, Gelfand JM, Barg FK: Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. J Invest Dermatol Feb 2019 Notes: Epub ahead of print.
150. Teague HL, Varghese NJ, Tsoi LC, Dey AK, Garshick MS, Silverman JI, Baumer Y, Harrington CL, Stempinski E, Elnabawi YA, Dagur PK, Cui K, Tunc I, Seifuddin F, Joshi AA, Stansky E, Purmalek MM, Rodante JA, Keel A, Aridi TZ, Carmona-Rivera C, Sanda GE, Chen MY, Pirooznia M, McCoy JP Jr, Gelfand JM, Zhao K, Gudjonsson JE, Playford MP, Kaplan MJ, Berger JS, Mehta NN: Neutrophil Subsets, Platelets, and Vascular Disease in Psoriasis. JACC Basic Transl Sci 4(1): 1-14, Feb 2019.
151. Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, Grayson MH, Margolis DJ, Mitchell L, Silverberg JI, Schwartz L, Simpson EL, Ong PY: Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. J Invest Dermatol 139(3): 583-90, Mar 2019.
152. Elnabawi YA, Dey AK, Goyal A, Groenendyk JW, Chung JH, Belur AD, Rodante J, Harrington CL, Teague HL, Baumer Y, Keel A, Playford MP, Sandfort V, Chen MY, Lockshin B, Gelfand JM, Bluemke DA, Mehta NN: Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 115(4): 721-28, Mar 2019.
153. Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Musiek A, Ortega-Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG: Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. JAMA Dermatol 155(4): 448-54, Apr 2019.
154. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Fuxench ZC, Simpson EL: Health Utility Scores of Atopic Dermatitis in US Adults. J Allergy Clin Immunol Pract 7(4): 1246-52, Apr 2019.
155. Barbieri JS, Gelfand JM: Responsiveness of the EuroQol 5-Dimension 3-Level instrument, Dermatology Life Quality Index (DLQI) and DLQI-Relevant for patients with psoriasis in the U.S.A. Br J Dermatol May 2019 Notes: Epub ahead of print.
156. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH,

- Ong PY, Fuxench ZC, Simpson EL: Atopic Dermatitis in US Adults: From Population to Health Care Utilization. J Allergy Clin Immunol Pract 7(5): 1524-32, May - Jun 2019.
157. Barbieri JS, Gelfand JM: Influence of "Not Relevant" Responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States. JAMA Dermatol 155(6): 743-45, Jun 2019.
158. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Chiesa Fuxench ZC, Simpson EL, Ong PY: Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults. J Allergy Clin Immunol Pract Jun 2019 Notes: Epub ahead of print.
159. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL: Measurement properties of Hospital Anxiety and Depression Scale used in atopic dermatitis in adults. J Invest Dermatol 139(6): 1388-91, Jun 2019.
160. Wan MT, Torigian DA, Alavi A, Alvarez J, Chiesa Fuxench ZC, Noe MH, Papadopoulos M, Shin DB, Takeshita J, Werner TJ, Mehta NN, Gelfand JM: Prevalence of clinically significant incidental findings by whole-body FDG-PET/CT scanning in moderate-to-severe psoriasis patients participating in clinical trials. J Am Acad Dermatol 80(6): 1630-39, Jun 2019.
161. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M: Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. J Am Acad Dermatol Jul 2019 Notes: Epub ahead of print.
162. Elnabawi YA, Oikonomou EK, Dey AK, Mancio J, Rodante JA, Aksentijevich M, Choi H, Keel A, Erb-Alvarez J, Teague HL, Joshi AA, Playford MP, Lockshin B, Choi AD, Gelfand JM, Chen MY, Bluemke DA, Shirodaria C, Antoniadis C, Mehta NN: Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index. JAMA Cardiol Jul 2019 Notes: Epub ahead of print.
163. Gelfand JM, Shin DB, Alavi A, Torigian DA, Werner T, Papadopoulos M, Takeshita J, Noe MH, Dey AK, Playford MP, Mehta NN: A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). J Invest Dermatol Jul 2019 Notes: Epub ahead of print.
164. Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY,

- Chiesa Fuxench ZC, Simpson EL, Gelfand JM: Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol 33(7): 1341-48, Jul 2019.
165. Groenendyk JW, Shukla P, Dey AK, Elnabawi YA, Aksentijevich M, Choi H, Genovese LD, Harrington CL, Natarajan B, Goyal A, Reddy AS, Rodante J, Kabbany MT, Sadek A, Al Najafi M, Playford MP, Joshi AA, Ahlman MA, Gelfand JM, Bluemke DA, Mehta NN: Association of aortic vascular uptake of 18FDG by PET/CT and aortic wall thickness by MRI in psoriasis: a prospective observational study. Eur J Nucl Med Mol Imaging Aug 2019 Notes: Epub ahead of print.
166. Noe MH, Shin DB, Doshi JA, Margolis DJ, Gelfand JM: Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database. J Drugs Dermatol 18(8): 745-50, Aug 2019.
167. Takeshita J, Eriksen WT, Raziano VT, Bocage C, Hur L, Shah RV, Gelfand JM, Barg FK: Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. J Invest Dermatol 139(8): 1672-79, Aug 2019.
168. Margolis DJ, Shin D, Noe MH, Wan MT, Bhate K, Wang S, Hoffstad O, Takeshita J, Gelfand JM: Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study. J Am Acad Dermatol 81(3), Sept 2019.
169. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL: Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol 181(3): 554-65, Sept 2019.
170. Smith MP, Ly K2, Thibodeaux Q2, Weerasinghe T2, Beck K2, Shankle L3, Armstrong AW4,5, Boas M4, Bridges A4, Doris F4, Gelfand JM4,6, Lafoy B4, Orbai AM4,7, Takeshita J4,6, Truman S4, Wan MT4,6, Wu JJ4,8, Siegel MP9, Bell SJ3, Bhutani T2, Liao W2,4.: Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. Dermatol Ther (Heidelb) 9(3): 511-23, Sept 2019.
171. Teague HL, Aksentijevich M, Stansky E, Silverman JI, Varghese NJ, Dey AK, Elnabawi Y, Goyal A, Dagur PK, Chen MY, McCoy JP, Playford MP, Hourigan C, Gelfand JM, Mehta NN: Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. J Invest Dermatol(19), 33234-8, Sept 2019 Notes: Epub ahead of print.
172. Munger E, Choi H, Dey AK, Elnabawi YA, Groenendyk JW, Rodante J, Keel A, Aksentijevich M, Reddy AS, Khalil N, Argueta-Amaya J, Playford MP,

- Erb-Alvarez J, Tian X, Wu C, Gudjonsson JE, Tsoi LC, Jafri MS, Sandfort V, Chen MY, Shah SJ, Bluemke DA, Lockshin B, Hasan A, Gelfand JM, Mehta NN: Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study. J Am Acad Dermatol Oct 2019 Notes: Epub ahead of print.
173. Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tying SK, Van Voorhees AS, Mehta NN, Gelfand JM: Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. J Am Acad Dermatol 81(4): 923-30, Oct 2019.
174. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL: Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults. J Invest Dermatol 139(10): 2090-97, Oct 2019.
175. Wan J, Takeshita J, Shin DB, Gelfand JM: Mental health impairment among children with atopic dermatitis: A United States population-based cross-sectional study of the 2013-2017 National Health Interview Survey. J Am Acad Dermatol Oct 2019 Notes: Epub ahead of print.
176. Wan J, Takeshita J, Shin DB, Gelfand JM: Mental health impairment among children with atopic dermatitis: A United States population-based cross-sectional study of the 2013-2017 National Health Interview Survey. J Am Acad Dermatol Oct 2019 Notes: Epub ahead of print.
177. Dey AK, Gaddipati R, Elnabawi YA, Ongstad E, Goyal A, Chung JH, Teague HL, Rodante JA, Sajja AA, Sorokin AV, Lateef SS, Aksentijevich M, Choi H, Reddy AS, Varghese NJ, Groenendyk J, Belur AD, Genovese L, Rivers JP, Lerman J, Kabbany MT, Harrington C, Ortiz J, Khalil N, Keel A, Baumer Y, Chen MY, Bluemke DA, Joshi AA, Kaplan MJ, Remaley AT, Playford MP, Karathanasis SK, Gelfand JM, Gupta R, Mehta NN: Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis. JAMA Dermatol Nov 2019 Notes: Epub ahead of print.
178. Noe MH, Gelfand JM, Bryer JS, Price SN, Judson MA, Rosenbach M: Responsiveness to Change and Establishment of the Minimal Clinically Important Difference for the Cutaneous Sarcoidosis Activity and Morphology Instrument. JAMA Dermatol Nov 2019 Notes: [Epub ahead of print.
179. Barbieri JS, Shin DB, Syed MN, Takeshita J, Gelfand JM: Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis. JAMA Dermatol Feb 2020 Notes: Epub ahead of print.

180. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M: Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 82(2): 377-88, Feb 2020.
181. Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Sarkar RP, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Dey AK, Werner TJ, Alavi A, Mehta NN: A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). J Invest Dermatol Feb 2020 Notes: Epub ahead of print.
182. Hamzavi IH, Lyons AB, Kohli I, Narla S, Parks-Miller A, Gelfand JM, Lim HW, Ozog D: Ultraviolet germicidal irradiation: possible method for respirator disinfection to facilitate reuse during COVID-19 pandemic. J Am Acad Dermatol Apr 2020 Notes: Epub ahead of print.
183. Lim HW, Feldman SR, Van Voorhees AS, Gelfand JM: Recommendations for phototherapy during the COVID-19 pandemic. J Am Acad Dermatol Apr 2020 Notes: Epub ahead of print.
184. Noe MH, Shin DB, Wehner MR, Margolis DJ, Gelfand JM: Opioid Prescribing in Adults with and without Psoriasis. J Am Acad Dermatol Apr 2020 Notes: Epub ahead of print.
185. Teague HL, Aksentijevich M, Stansky E, Silverman JI, Varghese NJ, Dey AK, Elnabawi Y, Goyal A, Dagur PK, Chen MY, McCoy JP, Playford MP, Hourigan C, Gelfand JM, Mehta NN: Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and Coronary Plaque. J Invest Dermatol 140(4): 912-15, Apr 2020.
186. Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM : The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol 83(5): 1523-26, Jul 2020 Notes: Online ahead of print.
187. Wan MT, Pearl RL, Chiesa Fuxench ZC, Takeshita J, Gelfand JM: Anticipated and Perceived Stigma Among Patients With Psoriasis. J Psoriasis Psoriatic Arthritis 5(3): 93-99, Jul 2020.
188. Syed MN, Shah M, Shin DB, Wan MT, Winthrop KL, Gelfand JM: Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and

- related symptoms in psoriasis patients - A meta-estimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol S0190-9622(20), Aug 2020 Notes: Online ahead of print.
189. Choi H, Uceda DE, Dey AK, Abdelrahman KM, Aksentijevich M, Rodante JA, Elnabawi YA, Reddy A, Keel A, Erb-Alvarez J, Teague H, Playford MP, Zhou W, Chen MY, Gelfand JM, Bluemke DA, Buckler A, Mehta NN: Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core: Results From a Prospective, Observational Study. Circ Cardiovasc Imaging 13(9), Sept 2020.
190. Wan J, Shin DB, Gelfand JM : Association between atopic dermatitis and learning disability in children. Allergy Clin Immunol Pract 8(8): 2808-10, Sep 2020.
191. Kothekar E, Revheim ME, Borja AJ, Hancin EC, Detchou DK, Werner TJ, Shin DB, Gelfand JM, Alavi A: Utility of FDG-PET/CT in clinical psoriasis grading: the PET-PASI scoring system. Am J Nucl Med Mol Imaging 10(5): 265-71, Oct 2020 Notes: eCollection 2020.
192. Lateef SS, Al Najafi M, Dey AK, Batool M, Abdelrahman KM, Uceda DE, Reddy AS, Svirydava MD, Nanda N, Ortiz JE, Prakash N, Rodante JA, Keel A, Zhou W, Chen MY, Playford MP, Teague HL, Tawakol AA, Gelfand JM, Powell-Wiley TM, Mehta NN: Relationship between chronic stress-related neural activity, physiological dysregulation and coronary artery disease in psoriasis: Findings from a longitudinal observational cohort study. Atherosclerosis Oct 2020.
193. Gonzalez-Cantero A, Reddy AS, Dey AK, Gonzalez-Cantero J, Munger E, Rodante J, Sanchez-Moya AI, Perez-Hortet C, Gonzalez-Calvin JL, Playford MP, Barderas MG, Ballester A, Jimenez-Gomez N, Jaén P, Chen MY, Gelfand JM, Mehta NN: Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. Eur J Prev Cardiol Nov 2020.
194. Sajja A, Abdelrahman KM, Reddy AS, Dey AK, Uceda DE, Lateef SS, Sorokin AV, Teague HL, Chung J, Rivers J, Joshi AA, Elnabawi YA, Goyal A, Rodante JA, Keel A, Alvarez JE, Lockshin B, Prussick R, Siegel E, Playford MP, Chen MY, Bluemke DA, Gelfand JM, Mehta NN: Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time. JCI Insight 5(22): e142534, Nov 2020.
195. Zhou W, Abdelrahman KM, Dey AK, Reddy A, Uceda DE, Lateef SS, Elnabawi YA, Anzenberg P, Al Najafi M, Rodante JA, Keel A, Ortiz J, Teague HL, Erb-Alvarez J, Singh D, Joshi AA, Playford MP, Chen MY, Gelfand JM, Remaley AT, Bluemke DA, Mehta NN: Association Among Noncalcified Coronary Burden, Fractional Flow Reserve, and Myocardial Injury in Psoriasis. J Am Heart Assoc 9(22): e017417, Nov 2020.

196. Barbieri JS, Mostaghimi A, Noe MH, Margolis DJ, Gelfand JM: Use of primary care services among patients with chronic skin disease seen by dermatologists. JAAD Page: 31-36, Dec 2020.
197. Dey AK, Teague HL, Adamstein NH, Rodante JA, Playford MP, Chen MY, Bluemke DA, Gelfand JM, Ridker PM, Mehta NN: Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. J Cardiovasc Comput Tomogr S1934-5925(20): 30504-9, Dec 2020 Notes: Online ahead of print.
198. Shields BE, Gelfand JM, Allen-Taylor L, Rosenbach M: Prevalence of Dermatitis Herpetiformis Within the iCureCeliac Patient-Powered Research Network-Patient Characteristics and Dietary Counseling. JAMA Dermatol 156(12): 1374-76, Dec 2020.
199. Teklu M, Zhou W, Kapoor P, Patel N, Dey AK, Sorokin AV, Manyak GA, Teague HL, Erb-Alvarez JA, Sajja A, Abdelrahman KM, Reddy AS, Uceda DE, Lateef SS, Shanbhag SM, Scott C, Prakash N, Svirydava M, Parel P, Rodante JA, Keel A, Siegel EL, Chen MY, Bluemke DA, Playford MP, Gelfand JM, Mehta NN: Metabolic Syndrome and its Factors are Associated with Non-Calcified Coronary Plaque Burden in Psoriasis: An Observational Cohort Study. J Am Acad Dermatol Dec 2020 Notes: Online ahead of print.
200. Syed MN, Shah M, Shin DB, Wan MT, Winthrop KL, Gelfand JM: Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol 84(1): 161-63, Jan 2021.
201. Gelfand JM, Wan J, Zhang H, Shin DB, Ogdie A, Syed MN, Egeberg A: Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. J Am Acad Dermatol Feb 2021.
202. González-Cantero A, Ortega-Quijano D, Álvarez-Díaz N, Ballester MA, Jimenez-Gomez N, Jaen P, González-Cantero J, González-Calvin JL, Barderas MG, Shin DB, Mehta NN, Gelfand JM: Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. J Invest Dermatol Apr 2021.
203. Uceda DE, Dey AK, Lateef SS, Abdelrahman K, Aksentijevich M, Reddy AS, Choi H, Rodante JA, Playford MP, Bluemke DA, Zhou W, Chen MY, Gelfand JM, Mehta NN: Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study. J Invest Dermatol 141(4): 913-16, Apr

- 2021.
204. Teklu M, Zhou W, Kapoor P, Patel N, Dey AK, Sorokin AV, Manyak GA, Teague HL, Erb-Alvarez JA, Sajja A, Abdelrahman KM, Reddy AS, Uceda DE, Lateef SS, Shanbhag SM, Scott C, Prakash N, Svirydava M, Parel P, Rodante JA, Keel A, Siegel EL, Chen MY, Bluemke DA, Playford MP, Gelfand JM, Mehta NN: Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study. J Am Acad Dermatol 84(5), May 2021.
205. Teklu M, Zhou W, Kapoor P, Patel N, Playford MP, Sorokin AV, Dey AK, Teague HL, Abdelrahman KM, Manyak GA, Erb-Alvarez JA, Shanbhag SM, Rodante JA, Keel A, Lockshin B, Chen MY, Gelfand JM, Bluemke DA, Wenger NK, Mehta NN: Sex Differences in Subclinical Coronary Atherosclerosis in Psoriasis by Coronary Computed Tomography Angiography. JACC Cardiovasc Imaging Jun 2021.
206. Gonzalez-Cantero A, Teklu M, Sorokin AV, Prussick R, González-Cantero J, Martin-Rodriguez JL, Patel N, Parel PM, Manyak GA, Teague HL, Rodante JA, Keel A, Pérez-Hortet C, Sánchez-Moya AI, Jiménez N, Ballester A, Solis J, Fernandez-Friera L, Barderas MG, Gonzalez-Calvin JL, Jaen P, Playford MP, Dey AK, Gelfand JM, Mehta NN: Subclinical Liver Disease is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies. J Invest Dermatol Jul 2021.
207. Meer E, Thrastardottir T, Wang X, Dubreuil M, Chen Y, Gelfand JM, Love TJ, Ogdie A: Risk factors for diagnosis of psoriatic arthritis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis: A set of parallel case-control studies. J Rheumatol 49(1): 53-59, Aug 2021.
208. Ogdie A, Shin DB, Love TJ, Gelfand JM: Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology (Oxford) Sep 2021.
209. Wan J, Shin DB, Gelfand JM: Treatment utilization and drug survival of systemic medications among commercially insured children with psoriasis. Pediatr Dermatol Sep 2021.
210. Barbieri JS, Gelfand JM: Patient-Reported Outcome Measures as Complementary Information to Clinician-Reported Outcome Measures in Patients With Psoriasis. JAMA Dermatol Oct 2021.
211. Meer E, Merola JF, Fitzsimmons R, Love TJ, Wang S, Shin D, Chen Y, Xie S, Choi H, Zhang Y, Scher JU, Ritchlin CT, Gelfand JM, Ogdie A: Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis Oct 2021.

212. Keller K, Hobohm L, Ostad MA, Karbach S, Espinola-Klein C, Münzel T, Gelfand JM, Konstantinides SV, Steinbrink K, Gori T: Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism. Int J Cardiol Nov 2021.
213. Wan J, Shin DB, Syed MN, Abuabara K, Lemeshow AR, Gelfand JM: Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study. Br J Dermatol Nov 2021.
214. Noe MH, Wan MT, Mostaghimi A, Gelfand JM; Pustular Psoriasis in the US Research Group, Agnihothri R, Armstrong AW, Bhutani T, Bridges A, Brownstone N, Butt M, Duffin KPC, Carr C, Creadore A, DeNiro KL, Desai S, Dominguez AR, Duffy EK, Fairley JA, Femia A, Gudjonsson JE, Kaffenberger JA, Katz KL, Kirby JS, Le ST, Martinez E, Maverakis E, Myers B, Naik HB, Nelson CA, Ortega-Loayza AG, Plovanch ME, Rangel LK, Ravi V, Reddy VD, Saleh JZ, Sandhu JK, Shakshouk H, Shields BE, Sharif-Sidi Z, Smith J, Steahr A, Toussi A, Wanat KA, Wang B, Wei BM, Weinhammer A, Worswick SD, Yang A: Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States. JAMA Dermatol 158(1): 68-72, Jan 2022.
215. Noe MH, Wan MT, Mostaghimi A, Gelfand JM; Pustular Psoriasis in the US Research Group, Agnihothri R, Armstrong AW, Bhutani T, Bridges A, Brownstone N, Butt M, Duffin KPC, Carr C, Creadore A, DeNiro KL, Desai S, Dominguez AR, Duffy EK, Fairley JA, Femia A, Gudjonsson JE, Kaffenberger JA, Katz KL, Le ST, Martinez E, Maverakis E, Myers B, Naik HB, Nelson CA, Ortega-Loayza AG, Plovanch ME, Rangel LK, Ravi V, Reddy VD, Saleh JZ, Kirby JS, Sandhu JK, Shakshouk H, Shields BE, Sharif-Sidi Z, Smith J, Steahr A, Toussi A, Wanat KA, Wang B, Wei BM, Weinhammer A, Worswick SD, Yang A: Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States. JAMA Dermatol 158(1): 73-78, Jan 2022.
216. Barbieri JS, Beidas RS, Gondo GC, Fishman J, Williams NJ, Armstrong AW, Ogdie AR, Mehta N, Gelfand JM: Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatol 158(3): 252-59, Mar 2022.
217. Berg AR, Hong CG, Svirydava M, Li H, Parel PM, Florida E, O'Hagan R, Pantoja CJ, Lateef SS, Anzenberg P, Harrington CL, Ward G, Zhou W, Sorokin AV, Chen MY, Teague HL, Buckler AJ, Playford MP, Gelfand JM, Mehta NN: Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study. J Invest Dermatol Jun 2022.

Research Publications, peer-reviewed reviews:

1. Clancy TE, Fiks AG, Gelfand JM, et al.: A Call for Health Policy Education in the Medical School Curriculum. Journal of the American Medical Association 274:

1084-1085, 1995.

2. Sapadin AN, Gelfand JM, Gumprecht J, and Rudikoff D: Acute Mucocutaneous Eruption in a Homosexual Male. International Journal of Dermatology 37: 436-438, 1998.
3. Gelfand JM, Lee P, Margolis R, and Johnson RA : An Asymptomatic Penile Plaque with Regional Lymphadenopathy. Archives of Dermatology 135: 845, 1999.
4. Lebwohl M, Gelfand JM, and Tan MH: Clinically Significant Therapeutic Interactions for the Practicing Dermatologist. Advances in Dermatology 14: 1-26, 1999.
5. Sapadin AN, Gelfand JM, Howe KL, Phelps RG, Grand D, and Rudikoff D : Dermatofibrosarcoma Protuberans in Two Patients with Acquired Immunodeficiency Syndrome. Cutis 65: 85-88, 2000.
6. Gelfand JM, Mirza N, Kantor J, Yu G, Reale D, Bondi E, and Junkins-Hopkins JM: Nodular Fasciitis. Archives of Dermatology 137: 719-721, 2001.
7. Wei H, Spencer J, Gelfand J, Phelps R, and Lebwohl M: The Isoflavone Genistein: A New Agent in Dermatology? Cosmetic Dermatology 14: 13-19, 2001.
8. Gelfand JM and Rudikoff D: Evaluation of Pruritus in Patients Infected with the Human Immunodeficiency Virus. Mount Sinai Journal of Medicine 68: 298-308, 2002.
9. Gelfand JM and Werth V: Evidence Based Medicine: Treatment of Bullous Nephigoid with Topical Corticosteroids, Review of a Randomized Controlled Clinical Trial. Archives of Dermatology 138: 1236-7, 2002.
10. Jih DM, Shapiro M, James WD, Levin M, Gelfand JM, Williams PT, Oakey RJ, Fakharzadeh S, and Seykora JT: Familial basaloid follicular hamartoma: lesional characterization and review of the literature. American Journal of Dermatopathology 2: 130-137, 2003.
11. Levy R, Gelfand JM, and Yan AC: Epidemiology of Atopic Dermatitis. Advances in Dermatology 21: 109-115, 2003.
12. Gelfand JM, Wasik MA, Vittorio C et al.: Progressive Epidermotropic CD8+/CD4 Primary Cutaneous CD30+ Lymphoproliferative Disorder in a Patient with Sarcoidosis. Journal of the American Academy of Dermatology 51: 304-308, 2004.
13. Hivnor CM, Nguyen V, Rook AH, Junkins-Hopkins J, Gelfand JM, Nasta S, Frank I, and Kim EJ: CD8+ Lymphoma in a Patient with Human Immunodeficiency Virus. Archives of Dermatology 141(10): 1321-2, October 2005.

14. Brown T, Zirvi M, Cotsarelis G, and Gelfand JM: Vitiligo-like Hypopigmentation Associated with Imiquimod Treatment of Genital Warts. Journal of the American Academy of Dermatology 52: 715-716, 2005.
15. Neimann AN, Porter S, and Gelfand JM: Epidemiology of Psoriasis. Expert Review of Dermatology 1: 63-75, 2006.
16. Feldman SR, Gelfand JM, Stein Gold L, and Jones SD: The Role of Topical Therapy for Patients with Extensive Psoriasis. Cutis 79: 18-31, 2007.
17. Kurd SK, Richardson SK, and Gelfand JM: An Update on the Epidemiology and Systemic Treatment of Psoriasis. Expert Review of Clinical Immunology 3: 171-185, 2007.
18. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, and Horn EJ: National Psoriasis Foundation Clinical Consensus on Disease Severity. Archives of Dermatology 143: 239-242, 2007.
19. Azfar RS and Gelfand JM: Psoriasis and Metabolic Disease: Epidemiology and Pathophysiology. Current Opinion in Rheumatology 20: 416-22, 2008.
20. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Brundy SM, Jarratt MT, Kruger JG, Ridker PM, Stone N, and Roberts WC: AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. American Journal of Cardiology 102: 1631-1643, 2008.
21. Kimball AB, Gladman D, Gelfand JM, Gordon G, Horn EJ, Korman NJ, Korver G, Kreuger GG, Strober BE, and Lebwohl, MG: National Psoriasis Foundation Clinical Consensus on Psoriasis Comorbidities and Recommendations for Screening. Journal of the American Academy of Dermatology 58: 1031-42, 2008.
22. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Kreuger GG, Mease P, Morrison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, and Horn L: From the Medical Board of the National Psoriasis Foundation: Monitoring and Vaccinations in Patients Treated with Biologics for Psoriasis. Journal of the American Academy of Dermatology 58: 94-105, 2008.
23. Richardson SK and Gelfand JM: Update on the Natural History and Systemic Treatment of Psoriasis. Advances in Dermatology 24: 172-196, 2008.
24. Dommasch E, and Gelfand JM: Is There Truly a Risk of Lymphoma from Biologic Therapies? Dermatologic Therapy 22: 418-30, 2009.

25. Mente, A, Korman NJ, Elemets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, and Bhushan R: Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis Section 4. Guidelines of Care for the Management and Treatment of Psoriasis with Traditional System Agents. Journal of the American Academy of Dermatology 61: 451-485, 2009.
26. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, and Bhushan R: Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis Section 3. Guidelines of Care for the Management and Treatment of Psoriasis with Topical Therapies. Journal of the American Academy of Dermatology 60: 643-659, 2009.
27. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, and Bhushan R: Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis Section 5. Guidelines of Care for the Management and Treatment of Psoriasis with Phototherapy and Photochemotherapy. Journal of the American Academy of Dermatology 61: 451-85, 2009.
28. Smith N, Weymann A, Tausk FA, and Gelfand JM: Complementary and alternative medicine for psoriasis: A qualitative review of the clinical trial literature. Journal of the American Academy of Dermatology 61: 841-56, 2009.
29. Gelfand JM and Abuabara K: Diet and Weight Loss as a Treatment for Psoriasis. Archives of Dermatology 146: 544-6, 2010.
30. Seminara NM and Gelfand JM: Assessing Long-Term Drug Safety: Lessons (Re)learned from Raptiva. Seminars in Cutaneous Medicine and Surgery 29: 16-19, 2010.
31. Tennis P, Gelfand JM, and Rothman KJ: Evaluation of Cancer Risk Related to Atopic Dermatitis and Use of Topical Calcineurin Inhibitors. British Journal of Dermatology 165(3): 465-473, September 2011.
32. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr.: Consensus Guidelines for the management of plaque psoriasis. Arch Dermatology 2012 148(1): 95 -102, Jan 2012.
33. Armstrong AW; Callis Duffin K; Garg, A; Gelfand Jm; Gottlieb AB; Krueger GG; Qureshi AA; Rosen CF.: Exploring priority research areas in Psoriasis and psoriatic arthritis from Dermatologists' perspective: A report from GRAPPA 2011

- Annual meeting. J Rheumatology 39(11): 2204-10, November 2012.
34. Gelfand JM and Yeung H.: Metabolic syndrome in patients with Psoriatic disease. Journal of Rheumatology (Supplement) 89: 24- 28, 2012.
 35. Helmick CG, Sacks JJ, Gelfand JM, Bebo B, Lee-Han H, Baird T, and Bartlett C: Psoriasis and psoriatic arthritis: A public health agenda. American Journal of Preventative Medicine 44(4): 424-6, Apr 2013.
 36. Dommasch E, Troxel AB, Gelfand JM: Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses. Journal of the American Academy of Dermatology 68(5): 863-5, May 2013.
 37. Armstrong AW, Gelfand JM, Boehncke WH, Armstrong EJ.: Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 Annual Meeting. J Rheumatology 40(8): 1434-7, Aug 2013.
 38. Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman Sr, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A: Research Gaps in Psoriasis: Opportunities for Future Studies. J Am Acad Dermatol 2013 70(1): 146-67, January 2014.
 39. Dommasch ED, Troxel AB, Gelfand JM: Counterpoint: A tale of two meta-analyses revisited. J Am Acad Dermatol. 70(2): 381-3, Feb 2014.
 40. Mehta NN, Gelfand JM: High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction. J Invest Dermatol 134(3): 592-5, March 2014.
 41. Armstrong AW, Gelfand JM, Garg A: Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: a report from the GRAPPA 2013 Annual Meeting. J Rheumatol. 41(6): 1233-6, June 2014.
 42. Belyaeva EA, Elenitsas R, Roth R, Miller C, Gelfand JM: Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous changes in a patient with psoriasis treated with adalimumab. JAAD Case Rep 1(5): 272-73, September 2015.
 43. Desai SR, Frieden IJ, Gelfand JM, High W, Kavanaugh A, Marghoob AA, Ozog DM, Rosen T, Stein Gold L, Strober B, Swanson N, Martin G: Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. J Clin Aesthet Dermatol Page: S4-S26, September 2015.
 44. Ogdie A, Gelfand JM: Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence. Curr Rheumatol Rep 17(10): 540, Oct 2015.

45. Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E: Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting. J Clin Aesthet Dermatol Page: S5 - S29, Sept 2016.
46. Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS: From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol 76(2): 290-98, February 2017.
47. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM: Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol 76(3): 393-403, Mar 2017 Notes: doi: 10.1016/j.jaad.2016.07.065.
48. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM: Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 76(3): 377-90, Mar 2017.
49. Osier E, Wang AS, Tollefson MM, Cordoro KM, Daniels SR, Eichenfield A, Gelfand JM, Gottlieb AB, Kimball AB, Lebwohl M, Mehta NN, Paller AS, Schwimmer JB, Styne DM, Van Voorhees AS, Tom WL, Eichenfield LF: Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatol 153(7): 698-704, Jul 2017 Notes: doi: 10.1001/jamadermatol.2017.0499.
50. Teague HL, Ahlman MA, Alavi A, Wagner DD, Lichtman AH, Nahrendorf M, Swirski FK, Nestle F, Gelfand JM, Kaplan MJ, Grinspoon S, Ridker PM, Newby DE, Tawakol A, Fayad ZA, Mehta NN: Unraveling Vascular Inflammation: From Immunology to Imaging. J Am Coll Cardiol 70(11): 1403-1412, Sept 2017 Notes: doi: 10.1016/j.jacc.2017.07.750. Review.
51. Noe MH, Gelfand JM: Research Techniques Made Simple: Pharmacoepidemiology Research Methods in Dermatology. J Invest Dermatol 138(2): e13-e18, Feb 2018 Notes: doi: 10.1016/j.jid.2017.10.026.
52. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A: Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 80(4): 1073-1113, Apr 2019 Notes: Epub ahead of print.

53. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmetts CA: Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4): 1029-72, Apr 2019 Notes: DOI: 10.1016/j.jaad.2018.11.057.
54. Elmetts CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A: Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol 81(3): 775-804, Sept 2019.
55. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT: National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 84(5): 1254-68, Jan 2021.

Contributions to peer-reviewed research publications, participation cited but not by authorship:

[none]

Research Publications, non-peer reviewed:

1. Shin TM, Shaikh WR, Eitzkorn JR, Sobanko JF, Margolis DJ, Gelfand JM, Chu EY, Elenitsas R, Miller CJ: Reply to: "Statistical and methodological issues" J Am Acad Dermatol 77(4): e115-e116, Oct 2017 Notes: doi: 10.1016/j.jaad.2017.05.030.

Abstracts (Last 3 years):

[none]

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

1. Gelfand JM and James WD: Sweet's Syndrome. Treatment of Skin Disease. Lebwohl M, Heyman WR, Berth-Jones J, and Coulson I (eds.). 2002 Notes: Mosby-London, England.

2. Gelfand JM and Margolis D: Decubitus Ulcers and Venous Ulcers. Dermatology in General Medicine, 6th Edition. Freedberg IM, Eisen AZ, Wolff K, Austen K, Frank-Goldsmith LA, Katz SI (eds.). 2003.
3. Gelfand JM, Dattani H, and Margolis D: The UK General Practice Research Database. Pharmacoepidemiology. Strom BL (eds.). John Wiley and Sons; West Sussex, England, 4th Edition, 2005 Notes:
4. Dick S, Gelfand JM, and James WD: Sweet's Syndrome, 2nd Edition. Treatment of Skin Disease. Lebwohl M, Heyman WR, Berth-Jones J, and Coulson I (eds.). Mosby- London, England, 2006.
5. Stergachis A et al. (Gelfand JM last author of 16 authors): Examples of Automated Databases. Textbook: Pharmacoepidemiology. Strom BL and Kimmel SE (eds.). Wiley. West Sussex, England, 2006.
6. Gelfand JM: Pharmacovigilance: Verifying that Drugs Remain Safe. Comprehensive Dermatologic Drug Therapy. Wolverton SE (eds.). Saunders Elsevier- Philadelphia, PA, 2nd Edition, 2007.
7. Gelfand JM: Long Term Treatment of Psoriasis: We're Half Way There with a Long Way to Go. Archives of Dermatology 143: 1191-1193, 2007.
8. Gelfand JM, Kurd SK, Neimann AL, Shin DB, Margolis DJ, and Troxel AB: Psoriasis and Risk of Myocardial Infarction - Reply. Journal of the American Medical Association 297: 362-363, 2007.
9. Richardson SR and Gelfand JM: Immunobiologicals, Cytokines, and Growth Factors in Dermatology. Dermatology in General Medicine. Goldsmith L (eds.). McGraw-Hill Education, 7th Edition, 2007.
10. Introcasso CE, Brunelli SM, Gelfand JM, Malik AS, Murashima M, Ahmed I, Feldman HI, and Margolis DJ: The Pitfalls of a Clinical Definition of Nephrogenic Systemic Fibrosis: Comment on the Article by Todd et al. Arthritis and Rheumatism 58: 1552, 2008.
11. Gelfand JM, Azfar RS, and Mehta NN: Psoriasis and Cardiovascular Risk: Strength in Numbers. Journal of Investigative Dermatology 130(4): 919-22, April 2010.
12. Abuabara K and Gelfand JM: Adherence to Treatment: Still the Forgotten Variable-Reply. Archives of Dermatology 146: 1184, 2010.
13. Dunbar RL and Gelfand JM: Seeing Red: Flushing Out Instigators of Niacin-Associated Skin Toxicity. Journal of Clinical Investigation 120: 2651-5, 2010.

14. Gelfand JM: Best of the Best: Top Accessed Article: Psoriasis Associated with Hyperleptinemia. Archives of Dermatology 146: 1057, 2010.
15. Miller CJ and Gelfand JM: Skin Cancer Management: A Practical Approach. Journal of the American Medical Association 303: 2086-87, 2010.
16. Ogdie A and Gelfand JM: Identification of Risk Factors for Psoriatic Arthritis: Scientific Opportunity Meets Clinical Need. Archives of Dermatology 146: 785-788, 2010.
17. Dommasch ED and Gelfand JM : Avoiding Palmar Ambiguity in the PREPI: a Handprint is Approximately 1% Body Surface Area- Reply. British Journal of Dermatology 164(3): 680, March 2011.
18. Gelfand JM, Mehta NN, and Langan S: Psoriasis and Cardiovascular Risk: Strength in Numbers- Part II. Journal of Investigative Dermatology 131: 1007-1010, April 2011.
19. Ogdie A, Langan S, Parkinson J, Dattani H, Kostev K, and Gelfand JM: Medical Record Databases. Pharmacoepidemiology- Philadelphia, PA; University of Pennsylvania. Strom BL, Kimmel S, Hennessy S (eds.). John Wiley & Sons, Incorporated, 5th Edition, 2012.
20. Gelfand JM; Wang S; Takeshita J; Robertson AD; Krueger GG; Callis Duffin K; VanVoorhees AS;; Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons from Clinical Trials. JAMA Dermatology 149: 491, 2013.
21. Takeshita J; Gelfand JM.: An Intensive Board Review Book with 1000 MCQs. Textbook of Internal Medicine. In Baliga RR(ed) (eds.). Blendon-Miller, 2013.
22. Dommasch ED, Troxel AB, and Gelfand JM.: A tale of two meta-analyses- revisited. Journal of the American Academy of Dermatology 2013; In press.
23. Mehta NN, and Gelfand JM.: High density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction. Journal of Investigative Dermatology 2013; In press.
24. Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A.: Research Gaps in psoriasis: opportunities for future studies. Journal of the American Academy of Dermatology. 2013; In press.
25. Dommasch ED, Troxel AB, and Gelfand JM: Counterpoint: A tale of two meta-analyses revisited. J Am Acad Dermatol 70(2): 381-3, February 2014.
26. Dommasch ED, Troxel AB, Gelfand JM: Counterpoint: A tale of two

- meta-analyses revisited. J Am Acad Dermatol 70(2): 381-3, February 2014.
27. Takeshita, J; Gelfand JM: Comparative Effectiveness Research: What it is and how to assess its quality. Evidence based Dermatology. 3rd ed. Williams HC; Bigby M; Herxheimer A; Naldi L; Rzany B; Dellavale R; Ran Y; Furue, M; (eds.). West Sussex, UK: John Wiley and Sons, Ltd, Aug 2014.
 28. Mehta NN and Gelfand JM: High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction. J Invest Dermatol 122: 269-90, 2014.
 29. Gelfand JM and Mehta NN: Aortic valve stenosis: a new cardiovascular co-morbidity of psoriasis. Eur Heart J 36(32): 2134-5, Aug 2015.
 30. Ogdie A, Troxel AB, Mehta NN, Gelfand JM: Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3. J Invest Dermatol. 135(9): 2148-50, Sep 2015.
 31. Wan J, Gelfand JM: Response to 'Kidney disease in moderate-to-severe psoriasis: a critical appraisal' Br J Dermatol 74(2): 270-1, Feb 2016.
 32. Gelfand JM: Psoriasis, obesity, and diabetes: Weighing the evidence. JAMA Dermatology 1: 753, 2016.
 33. Noe MH, Gelfand JM: Outcomes of Comorbidities with Biologics and Systemic Agents. Biologic and Systemic Agents in Dermatology. Paul S. Yamauchi. Cham (eds.). Switzerland, Springer International Page: 65-71, Jan 2018.
 34. Takeshita J, Gelfand JM: Psoriasis. Textbook of Internal Medicine: An Intensive Board Review Book with 1480 Multiple Choice Questions. Baliga RR Mar 2018 Notes: 1st Kindle Edition, Blendon-Miller, An imprint of MasterMedFacts LLC.
 35. Gelfand JM: Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer. J Am Acad Dermatol 1(79): 69-70, Jul 2018.
 36. Sanchez IM, Shankle L, Wan MT, Afifi L, Wu JJ, Doris F, Bridges A, Boas M, Lafoy B, Truman S, Orbai AM, Takeshita J, Gelfand JM, Armstrong AW, Siegel MP, Liao W: Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts. Dermatol Ther (Heidelb) 8(3): 405-23, Sept 2018.
 37. Takeshita J, Gelfand JM: Epidemiology of Psoriasis. Oxford Textbook of Psoriatic Arthritis. Oliver FitzGerald, Dafna Gladman (eds.). Oxford, UK: Oxford University Press Sept 2018.
 38. Gelfand JM, Wan MT: Psoriasis: a novel risk factor for type 2 diabetes. Lancet

Diabetes Endocrinol 6(12): 919-21, Dec 2018.

39. Hefele B, Langan SM, Pollins K, Gelfand JM: Engaging the Patient's Perspective in Clinical Trials Research. J Invest Dermatol 139(6): 1217-20, Jun 2019.
40. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmetts CA: Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol 82(3): 574, Jan 2020.
41. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmetts CA: Joint AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Non-Biological Therapies. J Am Acad Dermatol Feb 2020 Notes: Epub ahead of print.
42. Elmetts CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A: Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol S0190-9622(20), Jul 2020 Notes: Online ahead of print.
43. Lim HW, Feldman SR, Van Voorhees AS, Gelfand JM: Recommendations for phototherapy during the COVID-19 pandemic. J Am Acad Dermatol 83(1): 287-88, Jul 2020.
44. Wan MT, Shin DB, Winthrop KL, Gelfand JM: In response to: "Reply to Research Letter." J Am Acad Dermatol S0190-9622(20), Jul 2020 Notes: Online ahead of print.
45. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo RV 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT: National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. J

Am Acad Dermatol S0190-9622(20), Sep 2020.

46. Gelfand JM, Hefele BE: Clinical research post COVID-19: Embracing a new normal. J Invest Dermatol Sep 2020.
47. Horton L, Torres AE, Narla S, Lyons AB, Kohli I, Gelfand JM, Ozog DM, Hamzavi IH, Lim HW: Spectrum of virucidal activity from ultraviolet to infrared radiation. Photochem Photobiol Sci 19(10): 1262-70, Oct 2020.
48. Shin DB, Syed MN, Gelfand JM: Commentary. J Am Acad Dermatol S0190-9622(20): 32691-8, Oct 2020.
49. Wan MT, Shin DB, Winthrop KL, Gelfand JM: Reply to: "Do IL-17 inhibitors increase risk of respiratory tract infections?" J Am Acad Dermatol 83(4): e305-e306, Oct 2020.
50. Yu K, Syed MN, Bernardis E, Gelfand JM: Machine Learning Applications in the Evaluation and Management of Psoriasis: A Systematic Review. J Psoriasis Psoriatic Arthritis 5(4): 147-59, Oct 2020.
51. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT: National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments. J Am Acad Dermatol Jan 2021 Notes: Online ahead of print.
52. Gelfand JM, Dommasch ED, Mehta NN: Association Between Early Severe Cardiovascular Events and Ustekinumab Treatment? JAMA Dermatol 57(1), Jan 2021.
53. Elmetts CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A: Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 84(2): 432-70, Feb 2021.
54. Gelfand JM, Hefele BE: Clinical Research after COVID-19: Embracing a New Normal. J Invest Dermatol Mar 2021.
55. Gelfand JM, Syed MN: Response to Gau, Shuo-Yan's "Methotrexate Use and Liver

Outcomes in Psoriasis and Rheumatoid Arthritis Patients -a Commentary on "Risk of liver disease in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis receiving methotrexate: A population-based study" J Am Acad Dermatol. Page: S0190-9622, Aug 2021.

56. Gelfand JM, Syed MN: Response to: "Methotrexate Use and Liver Outcomes in Psoriasis and Rheumatoid Arthritis Patients: A Commentary on 'Risk of liver disease in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis receiving methotrexate: A population-based study'" J Am Acad Dermatol Aug 2021.
57. Lim HW, Feldman SR, Van Voorhees AS, Gelfand JM: Response to: "Successful implementation of phototherapy guidelines during the COVID-19 pandemic" J Am Acad Dermatol S0190-9622(21): 02268-4, Aug 2021.
58. Mehta NN, Gelfand JM: Is It Prime Time for Statin Therapy in Psoriasis? J Invest Dermatol 142(6): 1519-22, Jun 2022.

Books:

[none]

Alternative Media:

1. Gelfand JM: Psoriasis May Increase Risk For Certain Cancers. Journal Of The American Medical Association- ScienceDaily (<http://www.sciencedaily.com/releases/2003/11/031118073244.htm>) November 2003.
2. Gelfand JM: Psoriasis Increases Risk of Lymphoma. OncoLink Cancer Resources. Reuters Health (<http://www.oncolink.org/resources/article.cfm?c=3&s=8&ss=23&id=10271&month=11&year=2003>) November 2003.
3. Listed In Who's Who in America 2004.
4. JM Gelfand: Pharmacoepidemiology: Scrutinizing Drug Safety in Dermatology. Dermatology Times. Advanstar Communications (<http://dermatologytimes.modernmedicine.com/dermatologytimes/article/articleDetail.jsp?id=146983>) February 2005.
5. Gelfand, JM: Pharmacoepidemiology Dialogues in Dermatology 57(2), November 2005.
6. Listed In. Guide to America's Top Physicians. SLD Industries, 2005.
7. New Hope for Psoriasis Suffers. Bottom Line Health 19: 9-11, 2005.
8. Stein R : Smartest Are Most Often Dumb About Sunburns. Washington Post Page:

A02, July 2006.

9. Kowsmann P: Adult Psoriasis is Connected to Higher Risk of Heart Attacks. Wall Street Journal Page: D9, October 2006.
10. Ricks D: Psoriasis, heart attack link. Newsday Page: A24, October 2006.
11. Gelfand JM: Heart Risk Factors Prevalent in Psoriasis Patients. Reuters; American Academy of Dermatology (<http://reuters.com/article/idUSCOL46599120061124>) November 2006.
12. Painter K: Psoriasis Effects Everything. USA Today November 2006.
13. Gelfand JM: Listed in. Best Doctors in America (<http://www.bestdoctors.com/bd/WhoWeAre.php>) 2007-2016.
14. Gelfand JM: Psoriasis and Heart Disease. Health Talk interview (http://www.healthtalk.com/psoriasis/programs/11_677/index.cfm) January 2007.
15. Gelfand JM: Epidemiology and Psoriasis: Eye-Opening Results That Impact Patient Care. Dermatology Foundation Publication: Dermatology Focus 26(4): 1-6, 2007.
16. Gelfand JM: The Link Between Psoriasis and Cardiovascular Conditions. Interviewed on XM radio, Reach MD June 2009.
17. Gelfand JM: Health Problems Associated with Psoriasis National Psoriasis Foundation Webcast (http://www.psoriasis.org/netcommunity/events_cem_webex) August 2009.
18. Haran C: Under the Skin: A Link Between Psoriasis and Lymphoma. NY Daily Times November 2009.
19. Gelfand JM: Psoriasis Could Be Linked to Heart Attacks. KDKA 2 Pittsburgh (<http://kdka.com/video/?id=53427@kdka.dayport.com>) March 2010.
20. Gelfand JM: Psoriasis and Heart Attack Risk. Empowered Doctor (http://cw11.empowereddoctor.com/media_1007.html) March 2010.
21. Gelfand JM: Link Between Psoriasis and Your Heart. ABC 6 Action News (<http://abclocal.go.com/wpvi/story?sction=healthcheck&id=4647081>) March 2010.
22. Gelfand JM: Psoriasis May Increase Risk of Certain Cancers. Hindu (2003): n. pag. Web. March 2010.
23. Gelfand JM: The link between Psoriasis, Depression, Anxiety, and Suicidality.

"Doctor Radio", Interview on Sirius XM Radio September 2010.

24. SLD Industries, Inc.: Listed in. Guide to America's Top Dermatologists 2010.
25. Baldino Bonett, J: More Than Skin Deep. Penn Medicine. John Shea (eds.). 22(3): 26-30, February 2011.
26. Charles Bankhead: SID: More Evidence of Psoriasis Link to Metabolic Diseases. MedPage Today (<http://www.medpagetoday.com/PrimaryCare/PreventiveCare/26405>) May 2011.
27. Jan Bowers: Apples to Apples: Comparative effectiveness research gaining traction, finding best practices in the real world. Dermatology World Page: 28-32, January 2012.
28. Joel M. Gelfand: Behind the Numbers: Number Needed to Screen. Journal WATCH: Dermatology 20(1): 3, January 2012.
29. Joel M. Gelfand: Update on Psoriasis. "Doctor Radio", Interview on Sirius XM Radio February 2012.
30. Joel M. Gelfand: Psoriasis and Cardiovascular Disease. "Doctor Radio", Interview on Sirius XM Radio Apr 2013.
31. Gelfand JM: Management and Treatment of Psoriasis with Phototherapy. National Psoriasis Foundation Nov 2019 Notes: <https://www.youtube.com/watch?v=xXGNhqORvGc&feature=youtu.be>.

Patents:

Resiquimod for Treatment of T-Cell Lymphoma. Australia Patent Number 2014203896, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. Canada Patent Number 2,896,966, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. China Patent Number 2014800123283, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. European Patent Office Patent Number 14735313.0, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. Korea Patent Number 10-2015-7020899, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. Mexico Patent Number MX/A/2015/008773, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. Russia Patent Number 2015132959, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. World Patent Number PCT/US14/10339, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. Japan Patent Number TBD, 2014.

Resiquimod for Treatment of T-Cell Lymphoma. United States Patent Number 14/758,667, 2015.